US20210213235A1 - Systems And Methods Of Administering A Pharmaceutical Gas To A Patient - Google Patents
Systems And Methods Of Administering A Pharmaceutical Gas To A Patient Download PDFInfo
- Publication number
- US20210213235A1 US20210213235A1 US17/215,686 US202117215686A US2021213235A1 US 20210213235 A1 US20210213235 A1 US 20210213235A1 US 202117215686 A US202117215686 A US 202117215686A US 2021213235 A1 US2021213235 A1 US 2021213235A1
- Authority
- US
- United States
- Prior art keywords
- breath
- patient
- gas
- delivered
- pharmaceutical gas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 229910002091 carbon monoxide Inorganic materials 0.000 claims abstract description 63
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 claims description 69
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 44
- 230000036387 respiratory rate Effects 0.000 claims description 40
- 230000003434 inspiratory effect Effects 0.000 claims description 11
- 230000004044 response Effects 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 4
- 239000007789 gas Substances 0.000 abstract description 332
- 230000000241 respiratory effect Effects 0.000 abstract description 15
- 239000012159 carrier gas Substances 0.000 abstract description 7
- 238000002560 therapeutic procedure Methods 0.000 description 187
- 229940079593 drug Drugs 0.000 description 23
- 239000003814 drug Substances 0.000 description 22
- 230000029058 respiratory gaseous exchange Effects 0.000 description 14
- 230000037396 body weight Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 9
- 230000009471 action Effects 0.000 description 7
- 108010054147 Hemoglobins Proteins 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 108010003320 Carboxyhemoglobin Proteins 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 208000008384 ileus Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 230000000007 visual effect Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
- 108010061951 Methemoglobin Proteins 0.000 description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000012080 ambient air Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/12—Preparation of respiratory gases or vapours by mixing different gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0051—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes with alarm devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/021—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes operated by electrical means
- A61M16/022—Control means therefor
- A61M16/024—Control means therefor including calculation means, e.g. using a processor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/04—Tracheal tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/06—Respiratory or anaesthetic masks
- A61M16/0666—Nasal cannulas or tubing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/105—Filters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/20—Valves specially adapted to medical respiratory devices
- A61M16/201—Controlled valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/105—Filters
- A61M16/106—Filters in a path
- A61M16/107—Filters in a path in the inspiratory path
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0015—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors
- A61M2016/0018—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical
- A61M2016/0021—Accessories therefor, e.g. sensors, vibrators, negative pressure inhalation detectors electrical with a proportional output signal, e.g. from a thermistor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/0027—Accessories therefor, e.g. sensors, vibrators, negative pressure pressure meter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
- A61M16/0003—Accessories therefor, e.g. sensors, vibrators, negative pressure
- A61M2016/003—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter
- A61M2016/0033—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical
- A61M2016/0039—Accessories therefor, e.g. sensors, vibrators, negative pressure with a flowmeter electrical in the inspiratory circuit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0225—Carbon oxides, e.g. Carbon dioxide
- A61M2202/0233—Carbon monoxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/02—Gases
- A61M2202/0266—Nitrogen (N)
- A61M2202/0275—Nitric oxide [NO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/18—General characteristics of the apparatus with alarm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/33—Controlling, regulating or measuring
- A61M2205/3331—Pressure; Flow
- A61M2205/3334—Measuring or controlling the flow rate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/75—General characteristics of the apparatus with filters
Definitions
- the present invention relates to methods and systems for administering a pharmaceutical gas to a patient and, more particularly, to methods and systems for introducing carbon monoxide CO or nitric oxide NO to a patient in a predetermined quantity.
- the normal or conventional way of giving a pharmaceutical drug to a patient is to prescribe the dose based on the quantity of drug (usually in weight) per unit weight of the patient (e.g. mg/Kg) with the dose being specified to be delivered over a period of time or being repeated at specified intervals of time.
- This allows the user to control the quantity of drug and ensures the quantity of drug being delivered is in proportion to the patient's size. This is to reduce the patient to patient variability in response to the drug due to the size of the patient i.e. a 7 Kg baby will not get the same quantity of drug as a 80 Kg adult.
- the carbon monoxide gas needs to be delivered to the patients' alveoli where it can move across the alveolar membrane and into the blood stream where its action can take effect.
- the current dosing used in these cases is for the patient to breath at a specified concentration of CO in ppm for a specified period of time. Accurate dosing of CO for these treatments is important as CO reacts with the hemoglobin in the blood to form carboxyhemoglobin which means the hemoglobin is no longer able to carry oxygen to the tissues of the body. If too much CO is given, the patient may exhibit the toxic effects of CO for which it is usually known.
- this method of dosing CO can be associated with large variability in the actual dose being delivered to the animal/humans alveoli. This variability is because the quantity of CO being delivered to the animal/patient is dependent on a number of variables including, but not limited to, the patients tidal volume, respiratory rate, diffusion rate across the alveolar and ventilation/perfusion (V/Q) matching.
- the amount of CO delivered into a patient's alveoli can be determined by the ideal gas law as shown in the following equation:
- N PV /( R u T ) (1)
- N is the number of moles of the gas (mole)
- P is the absolute pressure of the gas (joule/m 3 )
- V is the volume of the particular gas (m 3 )
- R u is the universal gas constant
- 8.315 joule/mole-K is the absolute temperature (K).
- equation (1) reduces to:
- Equation (2) can be used to calculate the number of moles of gas delivered to a patient's alveolar volume over a period of time when given a specified concentration by using the following equation:
- N CO RR ⁇ t ⁇ C CO ⁇ 10 ⁇ 6 ⁇ 4.16 ⁇ 10 ⁇ 5 V a (3)
- C CO is the concentration of CO (ppm)
- V a is the alveolar volume (mL)
- RR is the respiratory rate (BPM)
- t is the time in minutes.
- the amount of CO gas in moles delivered to the patients alveoli over that period would be:
- a spontaneous patient's respiratory rate can vary widely from perhaps 8 to 20 breaths per minute depending on circumstances and the patient's alveolar volume per breath can also vary significantly from say 200 to 400 mL depending on the metabolic need.
- These variables can have a dramatic effect on the amount of gaseous drug being delivered to the patient over the same period of time. For instance, if the patients respiratory rate was 8 bpm and the alveolar volume was 200 mL, the CO dose delivered to the patients alveoli would have been 27.8 (mg). Likewise if the patients respiratory rate was 20 bpm and the alveolar volume was 400 mL, then the dose delivered to the patients alveoli would have been 139.2 (mg) thus representing a five-fold difference in the amount of drug being delivered.
- the quantity of gaseous drug a patient gets as measured in grams could vary substantially depending on the patient's ventilation pattern.
- the effect of these variables could mean that an individual patient could get significantly higher or lower doses of CO in grams and this could result in either high unsafe levels of carboxyhemoglobin or doses too low to be effective.
- the gaseous drug delivered to the alveoli will be taken up by the body's bloodstream (due to variables such as cardiac output and the diffusion coefficient of the gas) controlling the amount delivered to the alveoli takes away a major source of variability.
- the present invention relates to systems and methods for administering a pharmaceutical gas, such as carbon monoxide and nitric oxide, that allows a clinician to determine and control the desired quantity of the gas to be delivered to the patient.
- a pharmaceutical gas such as carbon monoxide and nitric oxide
- the methods determine the desired quantity of the pharmaceutical gas to be administered to the patient and then administers the desired quantity of the pharmaceutical gas irrespective of the patients respiratory patterns. If the prescription is specified as a total quantity of drug, then the method terminates the administration of the pharmaceutical gas when the desired total quantity has been administered to the patient.
- the amount of the pharmaceutical gas is delivered to the patient as a known desired quantity and that known desired quantity can be expressed in various units of measurement, such as, but not limited to, the weight of drug in micrograms ( ⁇ g), milligrams (mg), grams (g) etc., the moles of drug in nanomoles (nM), micromoles ( ⁇ M), millimoles (mM) moles (M) etc, or the volume of drug, at a known concentration or partial pressure, in microliters ( ⁇ L), milliliters (mL), liters (L) etc.
- the desired quantity of the pharmaceutical gas can also be expressed as an amount per unit of time for a period of time such as mg/hour for 2 hours.
- One or more embodiments of the invention also include systems for administering a pharmaceutical gas, such as carbon monoxide or nitric oxide, and the system includes an inlet means that can be connected to the source of the pharmaceutical gas and deliver the gas to a patient by means of a patient device.
- a patient device can be any device that actually introduces the pharmaceutical gas into the patient such as a nasal cannula, endotracheal tube, face mask or the like.
- a gas control system that controls the introduction of the quantity of a pharmaceutical gas from the gas source through the patient device. Again, therefore, the system provides a known quantity of gas to the patient.
- embodiments of the present invention allows a user to set a desired quantity of gaseous drug to be delivered to a patient's alveoli and for the system to then deliver that gaseous drug over multiple breaths until the prescribed amount has been delivered.
- the system and method may simply provide an alarm, visual and/or audible, to alert the user when the predetermined total quantity of the pharmaceutical gas has been administered to the patient and not actually terminate that administration. As such, the user is warned that the total predetermined desired quantity administered over the plurality of breaths has now been delivered to the patient so that the user can take the appropriate action, including a closer monitoring of the patient.
- One or more embodiments of the invention are directed to methods of administering a therapy gas to a patient, the therapy gas being at least one gas selected from CO and NO.
- the methods comprise determining a desired total quantity of therapy gas to be administered to the patient over a period of time over a plurality of breaths.
- a quantity of the therapy gas is administered to the patient during inspiration every n th breath of the plurality of breaths, wherein n is 1 or greater.
- the quantity of the therapy gas varied per n th breath to ensure that the desired total quantity over the period of time is administered independent of the respiratory pattern of the patient.
- the quantity of therapy gas per n th breath is in the range of a minimum quantity of therapy gas per breath and a maximum quantity of therapy gas per breath. In detailed embodiments, the quantity of therapy gas per n th breath is a function of one or more of a first respiratory rate, a first tidal volume of the patient and the patient's ideal body weight.
- the quantity of therapy gas per n th breath to be delivered is greater than the minimum quantity of therapy gas per breath and less than the maximum quantity of therapy gas per breath, the quantity of therapy gas per breath is administered on the n th breath, or when the quantity of therapy gas per n th breath is less than the minimum quantity of therapy gas per breath, administration of the quantity of therapy gas per n th breath is skipped for that n th breath, or when the quantity of therapy gas per n th breath is greater than the maximum quantity of therapy gas per breath, one or more of an alarm is triggered or the maximum quantity is delivered on the n th breath and a difference between the quantity of therapy gas per n th breath to be delivered and the maximum quantity of therapy gas per breath is carried to one or more subsequent breaths.
- a new quantity of therapy gas per n th breath is calculated.
- the maximum quantity of therapy gas per breath is administered on the n th breath and the difference between the quantity of therapy gas per n th breath and the maximum quantity of therapy gas per breath is added to one or more subsequent breaths.
- n is 2 or greater and the therapy gas is delivered during the n th breath. In some embodiments, no therapy gas is administered during the breaths that are not n th breaths.
- the quantity of therapy gas per n th breath is in the range of a minimum quantity of therapy gas per breath and a maximum quantity of therapy gas per breath. In specific embodiments, the quantity of therapy gas per n th breath is a function of one or more of a first respiratory rate, a first tidal volume of the patient and the patient's ideal body weight.
- the quantity of therapy gas per n th breath to be delivered is greater than the minimum quantity of therapy gas per breath and less than the maximum quantity of therapy gas per breath
- the quantity of therapy gas per n th breath is administered on the n th breath
- administration of the quantity of therapy gas per n th breath is skipped for that n th breath
- one or more of an alarm is triggered or the maximum quantity is delivered on the n th breath and a difference between the quantity of therapy gas per n th breath to be delivered and the maximum quantity of therapy gas per breath is carried to one or more subsequent breaths.
- a new quantity of therapy gas per n th breath is calculated.
- Detailed embodiments further comprise repeating the administration of the therapy gas on one or more subsequent breaths.
- the quantity of therapy gas per n th breath is greater than the maximum quantity of therapy gas per breath, the maximum quantity of therapy gas per breath is administered on the n th breath and the difference between the quantity of therapy gas per n th breath and the maximum quantity of therapy gas per breath is added to one or more subsequent breaths.
- Certain embodiments further comprise repeating the administration of the therapy gas on one or more subsequent breaths.
- the therapy gas is delivered to the patient's alveoli. In certain embodiments, the therapy gas is delivered to the patient during the first half of the inspiratory cycle.
- Additional embodiments are directed to methods of administering a therapy gas to a patient, the therapy gas being at least one of CO and NO.
- a desired total quantity of therapy gas to be administered to the patient over a period of time over a plurality of breaths is determined.
- a quantity of therapy gas to be delivered to the patient per n th breath is calculated, where calculating the quantity based on one or more of respiratory rate and quantity already given to the patient.
- Steps b) and c) are repeated varying the quantity of the therapy gas per n th breath to ensure that the desired total quantity over the period of time is maintained independent of the respiratory pattern of the patient.
- Some embodiments further comprise comparing the quantity of therapy gas to be delivered to determine if the quantity is in the range of a minimum quantity and a maximum quantity. In detailed embodiments, if the quantity of therapy gas to be delivered is lower than the minimum quantity, then the quantity of therapy gas delivered during the breath is zero and the quantity of therapy gas to be delivered is added to one or more subsequent breaths. In specific embodiments, wherein if the quantity of therapy gas to be delivered is greater than the maximum quantity, then performing one or more of activating an alarm, determining the difference between the quantity of therapy gas to be delivered and the maximum quantity, administering the maximum quantity or adding the difference between the quantity of therapy gas to be delivered and the maximum quantity to one or more subsequent breaths.
- FIG. 1 For embodiments of the invention, are directed to systems for administering a therapy gas to a patient having a respiratory pattern, the therapy gas being at least one gas selected from CO and NO.
- the system comprises an inlet to connect to a source of therapy gas, an outlet to connect to a device that introduces the therapy gas to the patient, a setting control to determine the desired quantity of therapy gas to be delivered to the patient over a plurality of breaths, and a gas control system to deliver the desired quantity of the therapy gas to the patient during inspiration by the patient over the plurality of breaths independent of the patient's respiratory pattern.
- the gas control system is configured to calculate a quantity of therapy gas to be delivered to the patient per n th breath, calculating the quantity based on one or more of respiratory rate and quantity already given to the patient, administer the quantity of the therapy gas to the patient's alveoli during the first half of the inspiratory cycle for every n th breath of the plurality of breaths, n being greater than 1 averaged over the period of time, and repeat steps a) and b) varying the quantity of the therapy gas per breath to ensure that the desired total quantity over the period of time is maintained independent of the respiratory pattern of the patient.
- FIGS. 1 and 2 are views of a front panel of an apparatus for carrying out the present invention showing different user options
- FIG. 3 is a schematic view of the present invention used with a spontaneously breathing patient
- FIG. 4 is a schematic view of the present invention used with a patient being breathed by means of a ventilator;
- FIG. 5 shows a flowchart of an exemplary method of administering a therapy gas to a patient according to one or more embodiments of the invention.
- FIG. 1 there is shown a front view of an apparatus that can be used in carrying out the present invention.
- a front panel 10 that can be a part of the apparatus and on that panel there are input setting knobs and displays which allow the user to set and monitor the amount of CO that is to be delivered to the patient.
- the means for determining the desired quantity of CO to be delivered is by means of an input setting knob 12 with the set amount being shown on the setting display 8 .
- the units shown in FIG. 1 are in milligrams per kilogram that is, the units are measured in a dosage per kilogram of the patient's ideal body weight.
- there is a further input 14 whereby the user can enter the patient's ideal body weight in kilograms with the amount also displayed on the setting display 8 .
- the user can set the quantity of the pharmaceutical gas to be administered to the patient in proportion to the size of the patient and which reduces the patient to patient variability in response to the pharmaceutical gas due to the size of the patient, i.e. a 7 kilogram baby will not be administered the same quantity of the pharmaceutical gas as a 80 kilogram adult.
- the front panel 10 also has a monitor display 6 which can display total dose of CO (mg) to be delivered (shown at 16 ) as calculated for multiplying the dosage/kg by the patients ideal body weight in kg.
- the system determines the amount of pharmaceutical gas that is to be delivered in each breath and the amount of time and/or the number of breaths that it will take to deliver the total desired quantity of drug.
- the monitor display 6 can also display a running total of the delivered dose of CO (mg) (shown at 17 ) as it is delivered to the patient so the user can monitor the progress of the treatment. This can be updated each breath as more pharmaceutical gas is delivered.
- FIG. 1 the units illustrated in FIG. 1 are in metric units, however, it can be seen that other units of mass and volume could be used in carrying out the present invention i.e. ounces and cubic inches and other designs of a front panel can be used as will later be understood.
- FIG. 2 there is shown a similar front panel 10 for the apparatus as shown in FIG. 1 but illustrating a different user setting option.
- the desired quantity of CO to be delivered to the patient is prescribed as a rate of delivery by means of input setting knob 13 and is in units of mg/hr of CO to be delivered.
- the device also allows the time duration (in hours) of treatment to be set by a means of an input setting knob 15 . If required, the input setting by input setting knob 15 could be set to continuous where the dose per hour would run continuously until the user changed the setting. With these input settings, the apparatus can calculate and display the desired quantity of the pharmaceutical gas to be administered to the patient.
- the front panel 10 also has a monitor display 6 which can display total dose of CO (mg) to be delivered (shown at 16 ) as calculated by multiplying the dosage/hr by the total time duration (hr.).
- the system determines the amount of pharmaceutical gas to be delivered in each breath and the amount of time and/or the number of breaths that it will take to deliver the total desired quantity of drug.
- the monitor display 6 can display a running total of the delivered dose of CO (mg) (shown at 17 ) as it is delivered to the patient so the user can monitor the progress of the treatment. This can be updated each breath as more pharmaceutical gas is delivered.
- FIGS. 1 and 2 illustrate two of the many options for setting the desired quantity and duration of pharmaceutical gas therapy. These options are not meant to be exhaustive and there are other setting options described or that can be understood from the detailed descriptions that follow.
- the gas control system can then determine the amount of pharmaceutical gas to be delivered in each breath and the amount of time and/or the number of breaths that it will take to deliver the desired quantity of pharmaceutical gas.
- the user can set the quantity of pharmaceutical gas to be delivered during each breath (M CO breath) and the gas control system calculates the number of breaths (n breaths ) which will be required to deliver the total quantity of pharmaceutical gas (M CO ) i.e.
- n breaths M CO /M CO breath (5)
- the value can be displayed on the front panel 12 by means of display 16 to inform the user of the number of breaths.
- the user can set the number of breaths (n breaths ) that will administer the total quantity of the pharmaceutical gas and the system calculates the amount per breath (M CO breath ) to be delivered.
- the value can be displayed on the front panel 10 to inform the user of the amount.
- the user could set the time duration for which the treatment is to be delivered over.
- the amount per breath would then be determined by calculating the quantity per minute and then, by monitoring the patients respiration rate in breaths per minute, the amount of breath can be calculated. This calculation can be repeated after every breath so any changes in the patients respiratory rate does not affect the overall quantity of gaseous drug being delivered.
- the amount per breath can be determined as a function of the patient's ideal body weight (IBW), the set dose per kilogram (M kg ) and the patient's monitored respiratory rate (RR) or combinations thereof;
- M CO breath f (IBW, M kg , RR) and the number of breaths can then be calculated as;
- n breaths M CO /M CO breath (7)
- the values can be displayed on the front panel 10 to inform the user of the amounts the device has selected.
- the device can calculate the quantity per breath to be delivered to the patient based on the current monitored respiratory breath rate (as determined by the breath trigger sensor). This quantity per breath can be recalculated after every breath when new information on the respiratory rate is available to ensure the quantity per unit of time is maintained even if the patient respiratory breath pattern changes over time.
- varying the quantity means that the calculated quantity is a dynamic value capable of being re-evaluated throughout administration of the therapy gas, not a fixed value. It is possible that the amount of gas delivered for each of the n th breaths is the same, or the amount for nearly every breath is the same. Varying the quantity does not mean that the amount of therapy gas delivered on every n th breath is different from the previous or subsequent breaths, merely that the value could be varied to compensate for changes in the patient's breathing pattern. For example, varying the quantity of therapy gas per breath may mean that the amount per breath is cut in half when the respiratory rate of the patient doubles.
- the device has two different amounts of delivery per breath, a high amount and a low amount.
- the device chooses which one to use based on the calculated quantity per unit of time being delivered over the past number of breaths. If the amount per unit of time is greater than required, it uses the low amount per breath until the situation corrects itself; likewise, if the quantity per unit of time is running low, then the unit switches to the high amount per breath.
- the device can also have programmed limits which restrict the maximum and minimum values that can be selected for M CO breath so that the system doesn't select inappropriately too high or too low values. These limits can be set to vary based on the patient's ideal body weight, or other indicator of the patient size such as the patient's height, or the respiratory rate of the patient.
- the aforesaid information is sufficient for the system of the present invention to deliver the dose to the patient and to determine the amount per breath, time of administration or other parameter in order to commence the administration of CO and to terminate that administration when the user set quantity of the pharmaceutical gas has been delivered to the patient.
- FIG. 3 there is shown a schematic of a system that can be used to carry out the present invention when the patient is breathing spontaneously.
- a patient device 18 that delivers the dosage of the pharmaceutical gas from the gas delivery system 22 to the patient 41 via a gas conducting conduit 19 .
- the patient device 18 can be any one of a variety of devices that actually directs the pharmaceutical gas into the patient and may be a nasal cannula, a mask, an endotracheal tube and the like.
- a source of the pharmaceutical gas by means of a gas supply tank 20 containing the pharmaceutical gas generally in a carrier gas.
- the pharmaceutical gas is carbon monoxide
- the conventional, commercially available carrier gas is air.
- the supply of carbon monoxide and air is provided in concentrations of 3000 ppm however, concentrations within the range of 1000 to 5000 ppm of CO in air are also possible alternatives.
- the carrier gas is conventionally nitrogen and the typical available concentrations range from 100 ppm to 1600 ppm.
- the supply tank 20 there is a tank pressure gauge 21 and a regulator 23 to bring the tank pressure down to the working pressure of the gas delivery system 22 .
- the pharmaceutical gas enters the gas delivery system 22 through an inlet 24 that can provide a ready connection between that delivery system 22 and the supply tank 20 via a conduit.
- the gas delivery system 22 has a filter 25 to ensure no contaminants can interfere with the safe operation of the system and a pressure sensor 27 to detect if the supply pressure is adequate and thereafter includes a gas shut off valve 26 as a control of the pharmaceutical gas entering the delivery system 22 and to provide safety control in the event the delivery system 22 is over delivering the pharmaceutical gas to the patient.
- the shut off valve 26 can be immediately closed and an alarm 42 sounded to alert the user that the gas delivery system has been disabled.
- the shut off valve 26 can be a solenoid operated valve that is operated from signals directed from a central processing unit including a microprocessor.
- the flow control system Downstream from the shut off valve 26 is a flow control system that controls the flow of the pharmaceutical gas to the patient through the patient device 18 .
- the flow control system comprises a high flow control valve 28 and a low control valve 30 and just downstream from the high and low flow control valves 28 , 30 , respectively, are a high flow orifice 32 and a low flow orifice 34 and the purpose and use of the high and low flow valves 28 , 30 and the high and low flow orifices 32 , 34 will be later explained.
- a gas flow sensor 36 is also located in the flow of pharmaceutical gas to the patient device 18 and, as shown, is downstream from the flow control system, however, the gas flow sensor 36 may alternatively be located upstream of the flow control system.
- a patient trigger sensor 38 When the patient breathes in during inspiration it creates a small sub atmospheric pressure in the nose or other area where the patient device 18 is located, and hence in the patient device 18 itself. The patient trigger sensor 38 detects this pressure drop and provides a signal indicative of the start of inspiration of the patient. Similarly, when the patient breathes out there is a positive pressure in the patient device 18 and the patient trigger sensor 38 detects that positive pressure and provides a signal indicative of the beginning of expiration. This allows the patient trigger sensor 38 to determine not only the respiratory rate of the patient but also the inspiratory and expiratory times.
- the CPU 40 may include a processing component such as a microprocessor to carry out all of the solutions to the equations that are used by the gas delivery system 22 to deliver the predetermined quantity of the pharmaceutical gas to a patient.
- the CPU 40 is connected to the front panel 10 where the user can enter settings and monitor therapy.
- the delivery system 22 of the present invention for spontaneous breathing can now be explained.
- the delivery system 22 detects by means of the patient trigger sensor 38 that inspiration has started, there is a signal that is provided to the CPU 40 to deliver a dose of a pharmaceutical gas (M CO breath) into the patient's inspiratory gas flow, preferably during the first 1 ⁇ 2 of the inspiratory cycle.
- M CO breath a pharmaceutical gas
- This amount per breath has been determined based on the desired quantity of pharmaceutical gas that has been set on the system and the calculations made in a) to g) described earlier.
- the actual volume of gas delivered during the breath depends on the concentration of the pharmaceutical gas in the carrier gas that is supplied by the supply tank 20 .
- a typical source concentration (C CO ) for CO would be 3000 ppm (range 500 to 5000).
- the volume of source gas (V d ) per breath to provide a dose per breath (M CO breath) when the source of CO is 3000 ppm is given by the following equation, combining equations 2, 3, 4 and 6;
- V d M CO breath/(28 ⁇ C CO ⁇ 4.16 ⁇ 10 ⁇ 11 ) (8)
- the delivery system 22 opens a flow control valve, such as high flow valve 28 or low flow valve 30 to allow the gas to flow to the patient until the volume per breath (V d ) has been delivered.
- a flow control valve such as high flow valve 28 or low flow valve 30 to allow the gas to flow to the patient until the volume per breath (V d ) has been delivered.
- the presence of the high flow orifice 32 and the low flow orifice 36 limits the flow of gas to a fixed set level during the period that the high or low flow valves 28 , 30 are open so the delivery system 22 can determine the period of time the high or low flow valves 28 , 30 should be open to deliver the volume per breath (V d ) required.
- the flow can be determined by the gas flow sensor 36 to monitor the gas flow to the patient device 18 and thus to the patient and can shut off the appropriate high or low flow control valve 28 , 30 when the desired predetermined quantity of pharmaceutical gas dose has been delivered to the patient.
- the use of multiple flow valves that is, the high flow valve 28 and the low flow valve 30 along with corresponding multiple orifices, high flow orifice 32 and low flow orifice 34 , can be used in parallel so as to provide high and low ranges of gas flow.
- the low flow gas flow through the low flow valve 30 could be set to 1 L/min and the high flow gas flow through the high flow control valve 28 could be set to 6 L/min.
- the flow range of the particular gas flow valve is selected to ensure that the volume of gas per breath (V d ) can be delivered to the patient in at least 1 ⁇ 2 the inspiratory time.
- the inspiratory time would be 1.66 seconds and half that would be 0.83 seconds.
- the time (t) taken to deliver a V d of 28 mL can be calculated as follows.
- That time is therefore well within 1 ⁇ 2 the inspiratory time allowed of 0.83 seconds.
- the delivery system 22 can also include monitoring and alarm features to alert the user if the delivery system 22 is not working correctly. Those alarm conditions can be determined by the CPU 40 and the alarm 42 activated to alert the user to the particular fault condition.
- the alarm 42 can be audible, visual or both and the alarm conditions can be any one or all of the following: no breath detected, low source gas pressure, inaccurate delivery of the volume per breath (V d ), over delivery of the volume per breath (V d ), under delivery of the volume per breath (V d ) and termination/completion of the delivery program.
- the CPU 40 may signal the gas shut off valve 26 and immediately cease any further delivery of the pharmaceutical gas and the alarm 42 also activated.
- the use of the alarm 42 can also be an alternative to actually shutting off the supply of the pharmaceutical gas to a patient when the predetermined desired quantity of pharmaceutical gas has been fully delivered to the patient.
- the delivery system 22 may, by means of the CPU 40 , activate the alarm 42 to alert the user that the total predetermined desired quantity of the pharmaceutical gas has been delivered. The user can then determine whether to manually deactivate the delivery system 22 or continue the delivery of the pharmaceutical gas under more watchful control of the patient's status.
- FIG. 4 there is shown a schematic view of a gas delivery system 44 used in conjunction with a patient being breathed by a ventilator 46 .
- a supply tank 20 that includes a conventional gas regulator 23 and pressure gauge 21 to supply the pharmaceutical gas along with the carrier gas to an inlet 24 in the gas delivery system 44 .
- a shut off valve 26 to control the overall flow of the pharmaceutical gas through the gas delivery system 44 .
- the high and low flow control valves 28 and 30 control the flow of the pharmaceutical gas through the gas delivery system 44 and, the high and low flow valves 28 , 30 operate as described with respect to the FIG. 3 embodiment with high and low flow orifices 32 , 34 located downstream of the flow control valves.
- the pharmaceutical gas is carried through an outlet conduit 70 to a patient device 72 that also receives the breathing gas from the ventilator 46 .
- the ventilator 46 delivers a flow of gas through the inspiratory limb 74 and gas is returned to the ventilator 46 through the expiratory limb 76 .
- the flow of gas from the ventilator 46 is thus supplemented by the flow of pharmaceutical gas from the gas delivery system 44 where that gas is mixed at or proximate to the patient device 72 for introduction into the patient 78 . Since all of the pharmaceutical gas is still delivered to the patient over the plurality of breaths, basically the CPU 40 can carry out the same determination of flows and the like as explained with respect to the FIG. 3 embodiment.
- the main difference between this FIG. 4 embodiment, and that shown in FIG. 3 is that the patient trigger sensor 66 is designed to operate in a way that works with a ventilator 46 .
- the ventilator 46 when the ventilator 46 provides gas flow to a patient during inspiration, it causes a positive pressure in the breathing circuit.
- the positive pressure is conducted through the outlet conduit 70 and is detected by the patient trigger sensor 66 and is recognized as the start of inspiration.
- This is the opposite to the embodiment of FIG. 3 where the patient breathes spontaneously and a negative pressure is generated during inspiration in the patient device 18 ; this negative pressure is conducted to the patient trigger sensor 38 of FIG. 3 and is recognized as the start of inspiration.
- the patient trigger sensor 38 of FIG. 3 and the patient trigger sensor of FIG. 4 could be the same pressure sensor and the gas delivery system 44 can be set for work with a ventilator or a spontaneously breathing patient.
- One or more embodiments of the invention are directed to methods of administering a therapy gas to a patient.
- a desired total quantity of therapy gas to be administered to the patient over a period of time over a plurality of breaths is determined.
- the desired total quantity of therapy gas can be measured in any suitable units including, but not limited to, mass of therapy gas, mass of the therapy gas active ingredient and moles of the therapy gas active ingredient.
- the desired total quantity of therapy gas to be administered to the patient can be entered directly into the device or can be calculated by the device.
- one or more of the following parameters may be input to the device: (a) the desired total quantity of therapy gas; (b) the period of time for delivery of the therapy gas; (c) the total number of breaths over which the delivery gas is delivered; and (d) the frequency of administration, i.e. choose the value of n such that the therapy gas is delivered every n th breath, wherein n is 1 or greater. Treatment may be repeated as necessary. It will be understood by those skilled in the art that other parameters may be entered.
- the quantity of the therapy gas is delivered to the patient during inspiration.
- the therapy gas is delivered to the patient's alveoli.
- substantially all of the therapy gas is delivered to the patient's alveoli.
- the term “substantially all” means that at least about 80%, 85%, 90% or 95% of the therapy gas is delivered to the alveoli. In some embodiments, “substantially all” means that a sufficient percentage of therapy gas is delivered to the alveoli so that there is little or no irritation of the respiratory track.
- n is 1 or greater.
- the therapy gas is delivered to the patient on each breath.
- n is 2, the therapy gas is delivered to the patient on every other breath.
- n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
- n is 2 or greater, conditions of skipped breathing are achieved, meaning therapy gas is skipped on certain breaths while administered on certain other breaths.
- the interval between delivery breaths can vary throughout the delivery of the total quantity depending on a number of conditions. For example, therapy gas may be delivered on breaths 1 , 3 , 5 , 8 , 10 , 12 , etc.
- the administration of the therapy gas is repeated for each n th breath.
- the therapy gas is delivered for 2 out of every 3 breaths, or for 3 out of every 5 breaths, or for 4 out of every 7 breaths, or for 2 out of every 5 breaths, or for 2 out of every 7 breaths, etc.
- certain embodiments provide that the delivery every n th breath does not need to follow a specific pattern. For example, as discussed in more detail below, certain breaths may be skipped for a variety of reasons, such as an amount to be delivered in a particular breath being less than a minimum delivery quantity. Breaths may also be skipped such that the gas is not delivered on literally every n th breath, but the therapy gas is delivered on average every n th breath. Also, the value of n may change during administration such that the therapy gas is delivered is every n 1 th breath for part of the administration, the therapy gas is delivered is every n 2 th breath for another part of the administration, the therapy gas is delivered every n 3 th breath for a third part of the administration, etc.
- the quantity of therapy gas provided at the n th breath is a function of one or more of a first respiratory rate, a first tidal volume of the patient and the patient's ideal body weight.
- the first respiratory rate and tidal volume can be measured prior to, at the beginning of, or during the treatment.
- One or more of the first respiratory rate and tidal volume can be used to calculate an initial amount of therapy gas to be delivered on each n th breath for a period of time to deliver the desired total quantity of therapy gas. After this initial respiratory rate is measured and the initial amount to be delivered per n th breath is calculated or determined, changes in the respiratory rate may occur and the calculated amount may need to be adjusted.
- a subsequent calculation of the amount of therapy gas to be delivered can be performed.
- the subsequent calculation can be done after any or all individual administration of therapy gas.
- the amount of therapy gas to be delivered during the n th breath can be recalculated after each individual delivery. As a result of the recalculations, the total quantity of therapy gas delivered is independent of the patient's respiratory rate, and the total quantity of therapy gas can be controlled to be the desired amount.
- the subsequent calculated rate would be about 50 ⁇ L per n th breath.
- this scenario would result in the patient having received about twice the amount of therapy gas as was originally intended by the end of the period of time for delivery of the gas.
- recalculating the amount of gas to be delivered throughout the delivery period may result in a more accurate amount of therapy gas provided to the patient and can help mitigate potential side effects of too much of the therapy gas. Accordingly, varying the amount per n th breath ensures that the desired total amount of therapy gas is delivered to the patient over the plurality of breaths.
- the quantity of the therapy gas per n th breath can be varied to ensure that the desired total quantity over the period of time is administered, independent of the respiratory pattern of the patient.
- the quantity of therapy gas delivered may be in the range of a minimum quantity and a maximum quantity.
- the minimum quantity and maximum quantity are functions of the device delivering the therapy gas.
- the minimum quantity may be the smallest amount that the device is capable of providing and the maximum quantity may be the maximum amount that the device is capable of providing. For example, if the smallest volume of therapy gas that the device is capable of releasing is 10 ⁇ L, then the concentration of the therapy gas multiplied by the smallest deliverable volume will give the smallest amount of therapy gas active that can be delivered.
- the quantity of therapy gas to be delivered per n th breath is greater than the minimum quantity and less than the maximum quantity
- the quantity of therapy gas per breath is administered on the n th breath.
- the therapy gas can be administered in many ways. For example, if the device is only capable of delivering a minimum of 10 ⁇ L, but the quantity to be delivered is 8 ⁇ L, the device can skip the amount to be delivered during this breath and add the amount (8 ⁇ L) to any of the subsequent breaths, or can divide the amount among two or more subsequent breaths.
- the device can deliver the minimum amount to be delivered (10 ⁇ L) and subtract the difference (2 ⁇ L) from a subsequent breath or divided the amount to be subtracted over two or more subsequent breaths.
- the quantity of therapy gas per breath is skipped and a new quantity of therapy gas per breath is calculated for subsequent doses.
- the new quantity can include the skipped amount in a single breath, or the new quantity can spread the skipped amount over multiple breaths.
- the maximum quantity of therapy gas per breath is administered and the difference between the calculated quantity of therapy gas for the n th breath and the maximum quantity of therapy gas is carried forward for later delivery on one or more subsequent breaths.
- the system may trigger one of many alarm conditions or can be set to automatically extend the period of time for delivery to ensure that the desired total amount of therapy gas is delivered.
- n 1 such that the therapy gas is administered every breath.
- some breaths may be skipped if the amount to be delivered in a given breath is less than the minimum quantity.
- the quantity that would have been delivered during this skipped breath may be added to any of the subsequent breaths or may be divided among two or more subsequent breaths.
- the therapy gas is administered every n th breath where n is 2 or greater. This means that the therapy gas is provided in a “skip breathing” regimen. Skip breathing may be desired as there can be an overall decrease in the amount and severity of adverse reactions including irritation due to the therapy gas.
- the patient can breathe ambient air, oxygenated air, pure oxygen, or a different therapy gas, depending on the desired treatment. In detailed embodiments, the patient breathes ambient air on inhalations not accompanied by therapy gas.
- the administration of quantities greater than the maximum amount can be handled differently than when therapy gas is delivered on every breath. If the amount to be delivered is greater than the maximum, the device may proceed in one or more of the following manners: (a) an alarm can be activated; (b) the maximum amount of therapy gas that can be delivered is delivered to the patient on the n th breath; and (c) the difference between the maximum amount and the quantity to be delivered is carried over to subsequent breaths or administrations. If the following breath is skipped as part of a skip breathing protocol, i.e. is not an n th breath, the carryover dose could be provided during the skipped breath or maintained until the next breath scheduled for dosing.
- the amount of therapy gas to be delivered can be calculated multiple times during the total administration time. The amount can be recalculated based on the number of breaths, the amount of time between measurements and after every breath, as desired by the administration protocol. When the quantity of the therapy gas to be delivered is skipped, for any reason, a new quantity of therapy gas per breath is calculated.
- the device can trigger an alarm, as described earlier.
- the administration can continue until manually or programmatically stopped.
- the delivery program i.e., the amount of therapy gas per period of time
- the administration of the therapy gas can be stopped until manually or programmatically restarted (i.e., a programmed pause between executions of the administration protocol). For example, if the program calls for delivery over a one hour period, the device can be programmed to wait for a specified period (e.g., 2 hours) after completion before restarting the administration program.
- Additional embodiments of the invention are directed to methods of treating pulmonary arterial hypertension (PAH), including those suffering from chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), etc.
- PAH pulmonary arterial hypertension
- COPD chronic obstructive pulmonary disease
- IPF idiopathic pulmonary fibrosis
- a desired total quantity of therapy gas to be delivered to a COPD patient over a period of time over a plurality of breaths is determined.
- the quantity is administered to the patient during inspiration every n th breath of the plurality of breaths, where n is 2 or greater.
- the quantity of therapy gas is varied per breath to ensure that the desired total quantity delivered over the period of time is maintained independent of the respiratory pattern of the patient.
- varying the quantity of the therapy gas per breath comprises determining the quantity of therapy gas to be delivered during the breath based on the respiratory rate of the patient and the amount of therapy gas already given to the patient. In other words, the desired total amount of therapy gas to be delivered to the patient over the plurality of breaths is ensured by varying the amount delivered per breath, as required by changes in the breathing pattern of the patient.
- FIG. 5 shows a flowchart for a detailed method 100 in accordance with one or more embodiments of the invention. It will be understood by those skilled in the art that the method outlined in FIG. 5 is merely a possible methodology and should not be taken as limiting the scope of the invention.
- the methods described provide for ability to manage the total quantity of therapy gas given over a period of time.
- Pertinent information related to the administration of the therapy gas and the program conditions 102 are entered into a device capable of delivering the therapy gas.
- the program conditions can explicitly state the necessary information for delivery, or can provide variables which the device can use to calculate the necessary information.
- the device determines if the approaching breath is an n th breath 104 , meaning that the device will administer the therapy gas on that breath. On a first pass through the process flow, the answer will likely be yes, leading the device to determine one or more physiological parameters 106 of the patient (e.g., respiratory rate and tidal volume).
- the physiological parameters can be measured by the device or transferred from another measuring device or can be manually entered into the device.
- the device can calculate the amount of therapy gas to be delivered to the patient 108 . This can be an initial calculation or a subsequent calculation.
- the calculated amount of therapy gas per breath may be compared 110 to a minimum quantity and a maximum quantity of deliverable gas.
- the minimum and maximum quantities as described previously, can be functions of the device, functions of the concentration of the therapy gas source, a function of the physiological parameters of the patient and combinations thereof. If the amount of therapy gas to be delivered is between the minimum and maximum quantities, the dose of therapy gas is delivered 112 to the patient on the next breath.
- the device can proceed with any or all of several below minimum amount options 114 .
- the device can withhold administration 116 of the therapy gas for that breath.
- the device can carryover 118 the amount not administered to one or more subsequent breaths.
- the minimum amount can be administered 120 resulting in an over-administration for that breath.
- the amount over-administered can then be reduced from one or more subsequent breaths.
- An alarm condition 122 e.g., audible, visual, or electronic, as described earlier, can be activated.
- the device can proceed with any or all of several above maximum amount options 124 .
- the device can trigger an alarm condition 122 as described above.
- the device can administer the maximum amount 126 and either discard the difference or carryover 118 the difference to subsequent breaths.
- carrying over the difference to subsequent breaths can result in the amount for each n th breath to be over the maximum.
- the device can be programmed to carryover the amount if, for example, the calculated amount to be delivered is an outlier or if subsequent breaths are skipped.
- the device determines if it has reached the end conditions 128 of the program (e.g., time, amount delivered, number of breaths). If the end condition has not been reached, the device can then check to see if the next breath is scheduled to receive a dose of therapy gas 104 . If yes, the method proceeds through one or more of the steps as previously described. If the following breath is not supposed to receive therapy gas, the device can determine if there is carryover from a previous breath 130 . If there is carryover and it is the delivery of therapy gas is allowed on the alternate breaths, the device can determine the amount of therapy gas per breath to deliver 108 . This can be as simple as delivering the carried over amount, or holding the amount for further subsequent breaths. If there are no carry over breaths 130 , the device can do nothing for the breath and restart the method at evaluating if the next breath is an n th breath 104 .
- the end conditions 128 of the program e.g., time, amount delivered, number of breaths.
- the method and device can proceed through one or more of various end condition actions 132 .
- the delivery of the therapy gas can be discontinued until manually or programmatically restarted 134 .
- An alarm can be triggered.
- Administration of the therapy gas can continue 136 under the same conditions (e.g., restarting the program 138 ) or with different conditions.
Landscapes
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
- This application is a continuation under 35 U.S.C. § 120 of U.S. patent application Ser. No. 16/156,453, filed Oct. 10, 2018, which is a continuation under 35 U.S.C. § 120 of U.S. patent application Ser. No. 14/551,186, filed Nov. 24, 2014, now U.S. Pat. No. 10,099,029, issued Oct. 16, 2018, which is a continuation under 35 U.S.C. § 120 of U.S. patent application Ser. No. 13/331,807, filed Dec. 20, 2011, now U.S. Pat. No. 8,893,717, issued Nov. 25, 2014, which is a continuation-in-part under 35
U.S.C. § 120 of U.S. patent application Ser. No. 12/430,220, filed Apr. 27, 2009, now U.S. Pat. No. 8,091,549, issued Jan. 10, 2012, and U.S. patent application Ser. No. 13/287,663, filed Nov. 2, 2011, now U.S. Pat. No. 8,517,015, issued Aug. 27, 2013, and U.S. patent application Ser. No. 13/284,433, filed Oct. 28, 2011, now U.S. Pat. No. 8,397,721, issued Mar. 19, 2013, which are continuations of U.S. patent application Ser. No. 11/231,554, filed Sep. 21, 2005, now U.S. Pat. No. 7,523,752, issued Apr. 28, 2009, the entire disclosures of which are hereby incorporated by reference herein. - The present invention relates to methods and systems for administering a pharmaceutical gas to a patient and, more particularly, to methods and systems for introducing carbon monoxide CO or nitric oxide NO to a patient in a predetermined quantity.
- The normal or conventional way of giving a pharmaceutical drug to a patient is to prescribe the dose based on the quantity of drug (usually in weight) per unit weight of the patient (e.g. mg/Kg) with the dose being specified to be delivered over a period of time or being repeated at specified intervals of time. This allows the user to control the quantity of drug and ensures the quantity of drug being delivered is in proportion to the patient's size. This is to reduce the patient to patient variability in response to the drug due to the size of the patient i.e. a 7 Kg baby will not get the same quantity of drug as a 80 Kg adult.
- In recent times there have been a number of gases which have been shown to have pharmaceutical action in humans and animals. Examples include Nitric Oxide (NO) Zapol et al U.S. Pat. No. 5,485,827 and more recently Carbon Monoxide (CO) Otterbein et al (U.S. Published Patent Application No. 2003/0219496). In the Otterbein patent application, CO is described as having a pharmacological action in a number of medical conditions including ileus and vascular disease.
- In these cases, the carbon monoxide gas needs to be delivered to the patients' alveoli where it can move across the alveolar membrane and into the blood stream where its action can take effect. The current dosing used in these cases is for the patient to breath at a specified concentration of CO in ppm for a specified period of time. Accurate dosing of CO for these treatments is important as CO reacts with the hemoglobin in the blood to form carboxyhemoglobin which means the hemoglobin is no longer able to carry oxygen to the tissues of the body. If too much CO is given, the patient may exhibit the toxic effects of CO for which it is usually known.
- There is a tight window for CO delivery between the therapeutic level and the level that causes carboxyhemoglobin above safe levels. Up until now CO has been delivered as a constant concentration in the gas breathed by the patient/animal for a specified period of time. For example in reference 3 of the Otterbein publication, (Example 2 pg 13) the therapeutic dose delivered to mice for the treatment of ileus was 250 ppm of CO for 1 hour.
- However, this method of dosing CO can be associated with large variability in the actual dose being delivered to the animal/humans alveoli. This variability is because the quantity of CO being delivered to the animal/patient is dependent on a number of variables including, but not limited to, the patients tidal volume, respiratory rate, diffusion rate across the alveolar and ventilation/perfusion (V/Q) matching.
- The amount of CO delivered into a patient's alveoli can be determined by the ideal gas law as shown in the following equation:
-
N=PV/(R u T) (1) - Where: N is the number of moles of the gas (mole) P is the absolute pressure of the gas (joule/m3) V is the volume of the particular gas (m3), Ru is the universal gas constant, 8.315 joule/mole-K and T is the absolute temperature (K).
- If we assume atmospheric pressure (101,315 joule/m3) and 20° C. (293 K) as the temperature and we express the volume in mL (10−6 m3), then equation (1) reduces to:
-
N=4.16×10−5 V (moles) (2) - Equation (2) can be used to calculate the number of moles of gas delivered to a patient's alveolar volume over a period of time when given a specified concentration by using the following equation:
-
N CO=RR·t·C CO·10−6·4.16×10−5 V a (3) - Where; CCO is the concentration of CO (ppm), Va is the alveolar volume (mL), RR is the respiratory rate (BPM) and t is the time in minutes.
- For example, if the CO dose for ileus in humans was 250 ppm of CO for one hour (60 minutes), the alveolar volume is 300 mL and the patients respiratory rate is 12 breaths per minute (bpm) then the amount of CO gas in moles delivered to the patients alveoli over that period would be:
-
N CO=12·60·250·10−6·4.16×10−5·300=2.25×10−3 moles - This can be converted into the mass of drug delivered (MCO) using the gram molecular weight of CO which is 28 as shown in the following equation:
-
M CO =N CO·28=63×10−3 g=63 mg (4) - However, although this works for a given set of assumptions, a spontaneous patient's respiratory rate can vary widely from perhaps 8 to 20 breaths per minute depending on circumstances and the patient's alveolar volume per breath can also vary significantly from say 200 to 400 mL depending on the metabolic need. These variables can have a dramatic effect on the amount of gaseous drug being delivered to the patient over the same period of time. For instance, if the patients respiratory rate was 8 bpm and the alveolar volume was 200 mL, the CO dose delivered to the patients alveoli would have been 27.8 (mg). Likewise if the patients respiratory rate was 20 bpm and the alveolar volume was 400 mL, then the dose delivered to the patients alveoli would have been 139.2 (mg) thus representing a five-fold difference in the amount of drug being delivered.
- This means, in the example of CO, the quantity of gaseous drug a patient gets as measured in grams could vary substantially depending on the patient's ventilation pattern. For a dose based on constant concentration and time, the effect of these variables could mean that an individual patient could get significantly higher or lower doses of CO in grams and this could result in either high unsafe levels of carboxyhemoglobin or doses too low to be effective. Although not all the gaseous drug delivered to the alveoli will be taken up by the body's bloodstream (due to variables such as cardiac output and the diffusion coefficient of the gas) controlling the amount delivered to the alveoli takes away a major source of variability.
- In addition, there is a need to administer NO to a patient in a predetermined quantity as described in “Cell-free hemoglobin limits nitric oxide bioavailabllity in sickle-cell disease”, Nature Medicine,
Volume 8,Number 12, December 2002, pages 1383 et seq. This paper describes the use of inhaled NO to react with cell free hemoglobin to form plasma methemoglobin and so reduce the ability of the cell free hemoglobin in the plasma to consume endogenously produced NO (FIG. 5, page 1386). The quantity of NO delivered to the patient blood needs to be equivalent to the amount of cell free hemoglobin that is in the patients plasma. The amount of NO delivered to a sample of sickle cell patients was 80 ppm of NO for 1.5 hours. However, there was variability in the amount of methemoglobin produced in individual patients as shown by the error bars on FIG. 4b. So, in a similar way to the CO example, a known quantity of NO needs to be delivered to a patient to provide the desired therapeutic effect and again it is important to remove any variability of delivery because of differences in the individual patient's respiratory pattern. - Accordingly, it would be advantageous to have a system and method of introducing pharmaceutical gases (such as carbon monoxide and nitric oxide) that allows for the precise control of a known quantity of the pharmaceutical gas to be delivered to the patients alveoli and which is not subject to change based on the patients respiratory patterns.
- Accordingly, the present invention relates to systems and methods for administering a pharmaceutical gas, such as carbon monoxide and nitric oxide, that allows a clinician to determine and control the desired quantity of the gas to be delivered to the patient. The methods determine the desired quantity of the pharmaceutical gas to be administered to the patient and then administers the desired quantity of the pharmaceutical gas irrespective of the patients respiratory patterns. If the prescription is specified as a total quantity of drug, then the method terminates the administration of the pharmaceutical gas when the desired total quantity has been administered to the patient.
- Thus, by the methods of various embodiments of the present invention, the amount of the pharmaceutical gas is delivered to the patient as a known desired quantity and that known desired quantity can be expressed in various units of measurement, such as, but not limited to, the weight of drug in micrograms (μg), milligrams (mg), grams (g) etc., the moles of drug in nanomoles (nM), micromoles (μM), millimoles (mM) moles (M) etc, or the volume of drug, at a known concentration or partial pressure, in microliters (μL), milliliters (mL), liters (L) etc. The desired quantity of the pharmaceutical gas can also be expressed as an amount per unit of time for a period of time such as mg/hour for 2 hours.
- One or more embodiments of the invention also include systems for administering a pharmaceutical gas, such as carbon monoxide or nitric oxide, and the system includes an inlet means that can be connected to the source of the pharmaceutical gas and deliver the gas to a patient by means of a patient device. That patient device can be any device that actually introduces the pharmaceutical gas into the patient such as a nasal cannula, endotracheal tube, face mask or the like. There is also a gas control system that controls the introduction of the quantity of a pharmaceutical gas from the gas source through the patient device. Again, therefore, the system provides a known quantity of gas to the patient.
- As such, embodiments of the present invention allows a user to set a desired quantity of gaseous drug to be delivered to a patient's alveoli and for the system to then deliver that gaseous drug over multiple breaths until the prescribed amount has been delivered.
- As a further embodiment, the system and method may simply provide an alarm, visual and/or audible, to alert the user when the predetermined total quantity of the pharmaceutical gas has been administered to the patient and not actually terminate that administration. As such, the user is warned that the total predetermined desired quantity administered over the plurality of breaths has now been delivered to the patient so that the user can take the appropriate action, including a closer monitoring of the patient.
- These and other features and advantages of the present invention will become more readily apparent during the following detailed description taken in conjunction with the drawings herein.
- One or more embodiments of the invention are directed to methods of administering a therapy gas to a patient, the therapy gas being at least one gas selected from CO and NO. The methods comprise determining a desired total quantity of therapy gas to be administered to the patient over a period of time over a plurality of breaths. A quantity of the therapy gas is administered to the patient during inspiration every nth breath of the plurality of breaths, wherein n is 1 or greater. The quantity of the therapy gas varied per nth breath to ensure that the desired total quantity over the period of time is administered independent of the respiratory pattern of the patient.
- In some embodiments, the quantity of therapy gas per nth breath is in the range of a minimum quantity of therapy gas per breath and a maximum quantity of therapy gas per breath. In detailed embodiments, the quantity of therapy gas per nth breath is a function of one or more of a first respiratory rate, a first tidal volume of the patient and the patient's ideal body weight. In specific embodiments, the quantity of therapy gas per nth breath to be delivered is greater than the minimum quantity of therapy gas per breath and less than the maximum quantity of therapy gas per breath, the quantity of therapy gas per breath is administered on the nth breath, or when the quantity of therapy gas per nth breath is less than the minimum quantity of therapy gas per breath, administration of the quantity of therapy gas per nth breath is skipped for that nth breath, or when the quantity of therapy gas per nth breath is greater than the maximum quantity of therapy gas per breath, one or more of an alarm is triggered or the maximum quantity is delivered on the nth breath and a difference between the quantity of therapy gas per nth breath to be delivered and the maximum quantity of therapy gas per breath is carried to one or more subsequent breaths. In certain embodiments, when the quantity of therapy gas per nth breath is skipped, a new quantity of therapy gas per nth breath is calculated. In detailed embodiments, when the quantity of therapy gas per nth breath is greater than the maximum quantity of therapy gas per breath, the maximum quantity of therapy gas per breath is administered on the nth breath and the difference between the quantity of therapy gas per nth breath and the maximum quantity of therapy gas per breath is added to one or more subsequent breaths.
- In one or more embodiments, n is 2 or greater and the therapy gas is delivered during the nth breath. In some embodiments, no therapy gas is administered during the breaths that are not nth breaths. In detailed embodiments, the quantity of therapy gas per nth breath is in the range of a minimum quantity of therapy gas per breath and a maximum quantity of therapy gas per breath. In specific embodiments, the quantity of therapy gas per nth breath is a function of one or more of a first respiratory rate, a first tidal volume of the patient and the patient's ideal body weight.
- In some embodiments, when the quantity of therapy gas per nth breath to be delivered is greater than the minimum quantity of therapy gas per breath and less than the maximum quantity of therapy gas per breath, the quantity of therapy gas per nth breath is administered on the nth breath, or when the quantity of therapy gas per nth breath is less than the minimum quantity of therapy gas per breath, administration of the quantity of therapy gas per nth breath is skipped for that nth breath, or when the quantity of therapy gas per nth breath is greater than the maximum quantity of therapy gas per breath, one or more of an alarm is triggered or the maximum quantity is delivered on the nth breath and a difference between the quantity of therapy gas per nth breath to be delivered and the maximum quantity of therapy gas per breath is carried to one or more subsequent breaths. In one or more embodiments, when the quantity of therapy gas per nth breath is skipped, a new quantity of therapy gas per nth breath is calculated. Detailed embodiments further comprise repeating the administration of the therapy gas on one or more subsequent breaths. In specific embodiments, when the quantity of therapy gas per nth breath is greater than the maximum quantity of therapy gas per breath, the maximum quantity of therapy gas per breath is administered on the nth breath and the difference between the quantity of therapy gas per nth breath and the maximum quantity of therapy gas per breath is added to one or more subsequent breaths. Certain embodiments further comprise repeating the administration of the therapy gas on one or more subsequent breaths.
- In some embodiments, when the quantity of therapy gas per nth breath is greater than the maximum quantity of therapy gas per breath, the maximum quantity of therapy gas per breath is administered on the nth breath and the difference between the quantity of therapy gas per nth breath and the maximum quantity of therapy gas per breath is administered over one or more subsequent breaths that are not an nth breath. In specific embodiments, the therapy gas is delivered to the patient's alveoli. In certain embodiments, the therapy gas is delivered to the patient during the first half of the inspiratory cycle.
- Additional embodiments are directed to methods of administering a therapy gas to a patient, the therapy gas being at least one of CO and NO. A desired total quantity of therapy gas to be administered to the patient over a period of time over a plurality of breaths is determined. A quantity of therapy gas to be delivered to the patient per nth breath is calculated, where calculating the quantity based on one or more of respiratory rate and quantity already given to the patient. The quantity of the therapy gas administered to the patient's alveoli during the first half of the inspiratory cycle for every nth breath of the plurality of breaths, n being greater than 1 averaged over the period of time. Steps b) and c) are repeated varying the quantity of the therapy gas per nth breath to ensure that the desired total quantity over the period of time is maintained independent of the respiratory pattern of the patient.
- Some embodiments further comprise comparing the quantity of therapy gas to be delivered to determine if the quantity is in the range of a minimum quantity and a maximum quantity. In detailed embodiments, if the quantity of therapy gas to be delivered is lower than the minimum quantity, then the quantity of therapy gas delivered during the breath is zero and the quantity of therapy gas to be delivered is added to one or more subsequent breaths. In specific embodiments, wherein if the quantity of therapy gas to be delivered is greater than the maximum quantity, then performing one or more of activating an alarm, determining the difference between the quantity of therapy gas to be delivered and the maximum quantity, administering the maximum quantity or adding the difference between the quantity of therapy gas to be delivered and the maximum quantity to one or more subsequent breaths.
- Further embodiments of the invention are directed to systems for administering a therapy gas to a patient having a respiratory pattern, the therapy gas being at least one gas selected from CO and NO. The system comprises an inlet to connect to a source of therapy gas, an outlet to connect to a device that introduces the therapy gas to the patient, a setting control to determine the desired quantity of therapy gas to be delivered to the patient over a plurality of breaths, and a gas control system to deliver the desired quantity of the therapy gas to the patient during inspiration by the patient over the plurality of breaths independent of the patient's respiratory pattern. The gas control system is configured to calculate a quantity of therapy gas to be delivered to the patient per nth breath, calculating the quantity based on one or more of respiratory rate and quantity already given to the patient, administer the quantity of the therapy gas to the patient's alveoli during the first half of the inspiratory cycle for every nth breath of the plurality of breaths, n being greater than 1 averaged over the period of time, and repeat steps a) and b) varying the quantity of the therapy gas per breath to ensure that the desired total quantity over the period of time is maintained independent of the respiratory pattern of the patient.
-
FIGS. 1 and 2 are views of a front panel of an apparatus for carrying out the present invention showing different user options; -
FIG. 3 is a schematic view of the present invention used with a spontaneously breathing patient; -
FIG. 4 is a schematic view of the present invention used with a patient being breathed by means of a ventilator; and -
FIG. 5 shows a flowchart of an exemplary method of administering a therapy gas to a patient according to one or more embodiments of the invention. - In the following detailed description, CO is used as the pharmaceutical gas but the description can also be valid for NO. Referring now to
FIG. 1 , there is shown a front view of an apparatus that can be used in carrying out the present invention. As can be seen, there is afront panel 10 that can be a part of the apparatus and on that panel there are input setting knobs and displays which allow the user to set and monitor the amount of CO that is to be delivered to the patient. - The means for determining the desired quantity of CO to be delivered is by means of an
input setting knob 12 with the set amount being shown on thesetting display 8. The units shown inFIG. 1 are in milligrams per kilogram that is, the units are measured in a dosage per kilogram of the patient's ideal body weight. Along with that input, there is afurther input 14 whereby the user can enter the patient's ideal body weight in kilograms with the amount also displayed on thesetting display 8. With those inputs, the user can set the quantity of the pharmaceutical gas to be administered to the patient in proportion to the size of the patient and which reduces the patient to patient variability in response to the pharmaceutical gas due to the size of the patient, i.e. a 7 kilogram baby will not be administered the same quantity of the pharmaceutical gas as a 80 kilogram adult. - The
front panel 10 also has amonitor display 6 which can display total dose of CO (mg) to be delivered (shown at 16) as calculated for multiplying the dosage/kg by the patients ideal body weight in kg. - Once the desired quantity of gaseous drug has been set on the device the system then determines the amount of pharmaceutical gas that is to be delivered in each breath and the amount of time and/or the number of breaths that it will take to deliver the total desired quantity of drug. The
monitor display 6 can also display a running total of the delivered dose of CO (mg) (shown at 17) as it is delivered to the patient so the user can monitor the progress of the treatment. This can be updated each breath as more pharmaceutical gas is delivered. - As stated, the units illustrated in
FIG. 1 are in metric units, however, it can be seen that other units of mass and volume could be used in carrying out the present invention i.e. ounces and cubic inches and other designs of a front panel can be used as will later be understood. - Referring to
FIG. 2 , there is shown a similarfront panel 10 for the apparatus as shown inFIG. 1 but illustrating a different user setting option. The desired quantity of CO to be delivered to the patient is prescribed as a rate of delivery by means ofinput setting knob 13 and is in units of mg/hr of CO to be delivered. In this option, the device also allows the time duration (in hours) of treatment to be set by a means of aninput setting knob 15. If required, the input setting byinput setting knob 15 could be set to continuous where the dose per hour would run continuously until the user changed the setting. With these input settings, the apparatus can calculate and display the desired quantity of the pharmaceutical gas to be administered to the patient. - Also, as in
FIG. 1 , thefront panel 10 also has amonitor display 6 which can display total dose of CO (mg) to be delivered (shown at 16) as calculated by multiplying the dosage/hr by the total time duration (hr.). Once the desired quantity of pharmaceutical gas has been set on the device, the system then determines the amount of pharmaceutical gas to be delivered in each breath and the amount of time and/or the number of breaths that it will take to deliver the total desired quantity of drug. As before, themonitor display 6 can display a running total of the delivered dose of CO (mg) (shown at 17) as it is delivered to the patient so the user can monitor the progress of the treatment. This can be updated each breath as more pharmaceutical gas is delivered. - As can be appreciated,
FIGS. 1 and 2 illustrate two of the many options for setting the desired quantity and duration of pharmaceutical gas therapy. These options are not meant to be exhaustive and there are other setting options described or that can be understood from the detailed descriptions that follow. - Once the desired quantity of gaseous drug has been set on the device, the gas control system can then determine the amount of pharmaceutical gas to be delivered in each breath and the amount of time and/or the number of breaths that it will take to deliver the desired quantity of pharmaceutical gas.
- There are a number of different approaches that the gas control system can use to determine the amount per breath and how long to deliver that dose so the desired quantity of pharmaceutical gas is delivered independent of the respiratory pattern of the patient:
- a) The user can set the quantity of pharmaceutical gas to be delivered during each breath (MCO breath) and the gas control system calculates the number of breaths (nbreaths) which will be required to deliver the total quantity of pharmaceutical gas (MCO) i.e.
-
n breaths =M CO /M CO breath (5) - Once the total number of breaths (nbreaths) required has been determined the value can be displayed on the
front panel 12 by means ofdisplay 16 to inform the user of the number of breaths. - b) The user can set the number of breaths (nbreaths) that will administer the total quantity of the pharmaceutical gas and the system calculates the amount per breath (MCO breath) to be delivered.
-
M CO breath =M CO /n breaths (mg) (6) - Once the amount per breath (MCO breath) to be delivered has been determined, the value can be displayed on the
front panel 10 to inform the user of the amount. - (c) The user could set the time duration for which the treatment is to be delivered over. The amount per breath would then be determined by calculating the quantity per minute and then, by monitoring the patients respiration rate in breaths per minute, the amount of breath can be calculated. This calculation can be repeated after every breath so any changes in the patients respiratory rate does not affect the overall quantity of gaseous drug being delivered.
- d) If the desired quantity of pharmaceutical gas was entered as a dose per Kg of the patient's ideal body weight (μg/kg) along with the patient's ideal body weight (Kg) then the amount per breath (MCO breath) can be determined as a function of the patient's ideal body weight (IBW), the set dose per kilogram (Mkg) and the patient's monitored respiratory rate (RR) or combinations thereof;
- MCO breath=f (IBW, Mkg, RR) and the number of breaths can then be calculated as;
-
n breaths =M CO /M CO breath (7) - Once the amount per breath (MCO breath) and the number of breaths (nbreaths) required to be delivered has been determined, the values can be displayed on the
front panel 10 to inform the user of the amounts the device has selected. - e) Instead of the ideal body weight (IBW) of the patient, the height and sex of the patient could be entered (which is how IBW is determined).
- f) If the desired quantity of pharmaceutical gas per unit of time is entered into the device, then the device can calculate the quantity per breath to be delivered to the patient based on the current monitored respiratory breath rate (as determined by the breath trigger sensor). This quantity per breath can be recalculated after every breath when new information on the respiratory rate is available to ensure the quantity per unit of time is maintained even if the patient respiratory breath pattern changes over time.
- g) There are also other ways of varying the quantity of pharmaceutical gas delivered per breath to ensure the quantity per unit of time is maintained even if the patients respiratory rate changes. As used in this specification and the appended claims, the term “varying the quantity” means that the calculated quantity is a dynamic value capable of being re-evaluated throughout administration of the therapy gas, not a fixed value. It is possible that the amount of gas delivered for each of the nth breaths is the same, or the amount for nearly every breath is the same. Varying the quantity does not mean that the amount of therapy gas delivered on every nth breath is different from the previous or subsequent breaths, merely that the value could be varied to compensate for changes in the patient's breathing pattern. For example, varying the quantity of therapy gas per breath may mean that the amount per breath is cut in half when the respiratory rate of the patient doubles.
- Another example is where the device has two different amounts of delivery per breath, a high amount and a low amount. The device chooses which one to use based on the calculated quantity per unit of time being delivered over the past number of breaths. If the amount per unit of time is greater than required, it uses the low amount per breath until the situation corrects itself; likewise, if the quantity per unit of time is running low, then the unit switches to the high amount per breath.
- The device can also have programmed limits which restrict the maximum and minimum values that can be selected for MCO breath so that the system doesn't select inappropriately too high or too low values. These limits can be set to vary based on the patient's ideal body weight, or other indicator of the patient size such as the patient's height, or the respiratory rate of the patient.
- The aforesaid information is sufficient for the system of the present invention to deliver the dose to the patient and to determine the amount per breath, time of administration or other parameter in order to commence the administration of CO and to terminate that administration when the user set quantity of the pharmaceutical gas has been delivered to the patient.
- Turning now to
FIG. 3 , there is shown a schematic of a system that can be used to carry out the present invention when the patient is breathing spontaneously. As can be seen, there is apatient device 18 that delivers the dosage of the pharmaceutical gas from thegas delivery system 22 to thepatient 41 via agas conducting conduit 19. As indicated, thepatient device 18 can be any one of a variety of devices that actually directs the pharmaceutical gas into the patient and may be a nasal cannula, a mask, an endotracheal tube and the like. - With the
FIG. 3 embodiment, there is a source of the pharmaceutical gas by means of agas supply tank 20 containing the pharmaceutical gas generally in a carrier gas. When the pharmaceutical gas is carbon monoxide, for example, the conventional, commercially available carrier gas is air. The supply of carbon monoxide and air is provided in concentrations of 3000 ppm however, concentrations within the range of 1000 to 5000 ppm of CO in air are also possible alternatives. In the case of NO as the pharmaceutical gas, the carrier gas is conventionally nitrogen and the typical available concentrations range from 100 ppm to 1600 ppm. - Accordingly, from the
supply tank 20, there is atank pressure gauge 21 and aregulator 23 to bring the tank pressure down to the working pressure of thegas delivery system 22. The pharmaceutical gas enters thegas delivery system 22 through aninlet 24 that can provide a ready connection between thatdelivery system 22 and thesupply tank 20 via a conduit. Thegas delivery system 22 has afilter 25 to ensure no contaminants can interfere with the safe operation of the system and apressure sensor 27 to detect if the supply pressure is adequate and thereafter includes a gas shut offvalve 26 as a control of the pharmaceutical gas entering thedelivery system 22 and to provide safety control in the event thedelivery system 22 is over delivering the pharmaceutical gas to the patient. In the event of such over delivery, the shut offvalve 26 can be immediately closed and analarm 42 sounded to alert the user that the gas delivery system has been disabled. As such, the shut offvalve 26 can be a solenoid operated valve that is operated from signals directed from a central processing unit including a microprocessor. - Downstream from the shut off
valve 26 is a flow control system that controls the flow of the pharmaceutical gas to the patient through thepatient device 18. In the embodiment shown, the flow control system comprises a highflow control valve 28 and alow control valve 30 and just downstream from the high and lowflow control valves high flow orifice 32 and alow flow orifice 34 and the purpose and use of the high andlow flow valves low flow orifices gas flow sensor 36 is also located in the flow of pharmaceutical gas to thepatient device 18 and, as shown, is downstream from the flow control system, however, thegas flow sensor 36 may alternatively be located upstream of the flow control system. - Next, there is a
patient trigger sensor 38. When the patient breathes in during inspiration it creates a small sub atmospheric pressure in the nose or other area where thepatient device 18 is located, and hence in thepatient device 18 itself. Thepatient trigger sensor 38 detects this pressure drop and provides a signal indicative of the start of inspiration of the patient. Similarly, when the patient breathes out there is a positive pressure in thepatient device 18 and thepatient trigger sensor 38 detects that positive pressure and provides a signal indicative of the beginning of expiration. This allows thepatient trigger sensor 38 to determine not only the respiratory rate of the patient but also the inspiratory and expiratory times. - Finally there is a
CPU 40 that communicates with thepatient trigger sensor 38, the high andlow flow valves valve 26 and other components in order to carry out the purpose and intent of the present invention. TheCPU 40 may include a processing component such as a microprocessor to carry out all of the solutions to the equations that are used by thegas delivery system 22 to deliver the predetermined quantity of the pharmaceutical gas to a patient. TheCPU 40 is connected to thefront panel 10 where the user can enter settings and monitor therapy. - The use of the
delivery system 22 of the present invention for spontaneous breathing can now be explained. When thedelivery system 22 detects by means of thepatient trigger sensor 38 that inspiration has started, there is a signal that is provided to theCPU 40 to deliver a dose of a pharmaceutical gas (MCO breath) into the patient's inspiratory gas flow, preferably during the first ½ of the inspiratory cycle. This amount per breath has been determined based on the desired quantity of pharmaceutical gas that has been set on the system and the calculations made in a) to g) described earlier. - The actual volume of gas delivered during the breath depends on the concentration of the pharmaceutical gas in the carrier gas that is supplied by the
supply tank 20. A typical source concentration (CCO) for CO would be 3000 ppm (range 500 to 5000). The volume of source gas (Vd) per breath to provide a dose per breath (MCO breath) when the source of CO is 3000 ppm is given by the following equation, combiningequations 2, 3, 4 and 6; -
V d =M CO breath/(28·C CO·4.16×10−11) (8) - Given that MCO=60×10−3 (g), CCO=3000 (ppm), nbreaths=600, then Vd=28.6 (mL).
- To deliver the volume of source gas per breath (Vd), that is, the pharmaceutical gas and the carrier gas, the
delivery system 22 opens a flow control valve, such ashigh flow valve 28 orlow flow valve 30 to allow the gas to flow to the patient until the volume per breath (Vd) has been delivered. The presence of thehigh flow orifice 32 and thelow flow orifice 36 limits the flow of gas to a fixed set level during the period that the high orlow flow valves delivery system 22 can determine the period of time the high orlow flow valves gas flow sensor 36 to monitor the gas flow to thepatient device 18 and thus to the patient and can shut off the appropriate high or lowflow control valve - As can be seen, to provide enough range to cover all the possible doses, the use of multiple flow valves, that is, the
high flow valve 28 and thelow flow valve 30 along with corresponding multiple orifices,high flow orifice 32 andlow flow orifice 34, can be used in parallel so as to provide high and low ranges of gas flow. For instance, the low flow gas flow through thelow flow valve 30 could be set to 1 L/min and the high flow gas flow through the highflow control valve 28 could be set to 6 L/min. The flow range of the particular gas flow valve is selected to ensure that the volume of gas per breath (Vd) can be delivered to the patient in at least ½ the inspiratory time. - As an example, if the patient was breathing at 12 breaths per minute and had an I:E ratio of 1:2 then the inspiratory time would be 1.66 seconds and half that would be 0.83 seconds.
- The time (t) taken to deliver a Vd of 28 mL can be calculated as follows.
-
t=V d60/(Q·1000) (secs) (9) - When Q (the flow of gas when the
high flow valve 28 is open)=6 L/mins t=0.28 (secs). - That time is therefore well within ½ the inspiratory time allowed of 0.83 seconds.
- The
delivery system 22 can also include monitoring and alarm features to alert the user if thedelivery system 22 is not working correctly. Those alarm conditions can be determined by theCPU 40 and thealarm 42 activated to alert the user to the particular fault condition. Thealarm 42 can be audible, visual or both and the alarm conditions can be any one or all of the following: no breath detected, low source gas pressure, inaccurate delivery of the volume per breath (Vd), over delivery of the volume per breath (Vd), under delivery of the volume per breath (Vd) and termination/completion of the delivery program. - Under certain conditions, such as when the
delivery system 22 is over delivering the pharmaceutical gas, theCPU 40 may signal the gas shut offvalve 26 and immediately cease any further delivery of the pharmaceutical gas and thealarm 42 also activated. - The use of the
alarm 42 can also be an alternative to actually shutting off the supply of the pharmaceutical gas to a patient when the predetermined desired quantity of pharmaceutical gas has been fully delivered to the patient. In such case, as an alternative to ceasing the further supply of the pharmaceutical gas to the patient, thedelivery system 22 may, by means of theCPU 40, activate thealarm 42 to alert the user that the total predetermined desired quantity of the pharmaceutical gas has been delivered. The user can then determine whether to manually deactivate thedelivery system 22 or continue the delivery of the pharmaceutical gas under more watchful control of the patient's status. - Turning now to
FIG. 4 , there is shown a schematic view of agas delivery system 44 used in conjunction with a patient being breathed by aventilator 46. In theFIG. 4 embodiment, again there is asupply tank 20 that includes aconventional gas regulator 23 andpressure gauge 21 to supply the pharmaceutical gas along with the carrier gas to aninlet 24 in thegas delivery system 44. Briefly summarizing the components of theFIG. 4 embodiment, since they are basically the same components as described with respect to theFIG. 3 embodiment, there can be afilter 25 and apressure sensor 27 in thegas delivery system 44. Again there is a shut offvalve 26 to control the overall flow of the pharmaceutical gas through thegas delivery system 44. - The high and low
flow control valves gas delivery system 44 and, the high andlow flow valves FIG. 3 embodiment with high andlow flow orifices - Again there is a
gas flow sensor 36 and apatient trigger sensor 66, both of which communicate with theCPU 40. With this embodiment, however, the pharmaceutical gas is carried through anoutlet conduit 70 to apatient device 72 that also receives the breathing gas from theventilator 46. As such, theventilator 46 delivers a flow of gas through theinspiratory limb 74 and gas is returned to theventilator 46 through theexpiratory limb 76. - The flow of gas from the
ventilator 46 is thus supplemented by the flow of pharmaceutical gas from thegas delivery system 44 where that gas is mixed at or proximate to thepatient device 72 for introduction into thepatient 78. Since all of the pharmaceutical gas is still delivered to the patient over the plurality of breaths, basically theCPU 40 can carry out the same determination of flows and the like as explained with respect to theFIG. 3 embodiment. The main difference between thisFIG. 4 embodiment, and that shown inFIG. 3 is that thepatient trigger sensor 66 is designed to operate in a way that works with aventilator 46. - For instance, when the
ventilator 46 provides gas flow to a patient during inspiration, it causes a positive pressure in the breathing circuit. The positive pressure is conducted through theoutlet conduit 70 and is detected by thepatient trigger sensor 66 and is recognized as the start of inspiration. This is the opposite to the embodiment ofFIG. 3 where the patient breathes spontaneously and a negative pressure is generated during inspiration in thepatient device 18; this negative pressure is conducted to thepatient trigger sensor 38 ofFIG. 3 and is recognized as the start of inspiration. As can be appreciated, thepatient trigger sensor 38 ofFIG. 3 and the patient trigger sensor ofFIG. 4 could be the same pressure sensor and thegas delivery system 44 can be set for work with a ventilator or a spontaneously breathing patient. - One or more embodiments of the invention are directed to methods of administering a therapy gas to a patient. A desired total quantity of therapy gas to be administered to the patient over a period of time over a plurality of breaths is determined. The desired total quantity of therapy gas can be measured in any suitable units including, but not limited to, mass of therapy gas, mass of the therapy gas active ingredient and moles of the therapy gas active ingredient. The desired total quantity of therapy gas to be administered to the patient can be entered directly into the device or can be calculated by the device. For example, one or more of the following parameters may be input to the device: (a) the desired total quantity of therapy gas; (b) the period of time for delivery of the therapy gas; (c) the total number of breaths over which the delivery gas is delivered; and (d) the frequency of administration, i.e. choose the value of n such that the therapy gas is delivered every nth breath, wherein n is 1 or greater. Treatment may be repeated as necessary. It will be understood by those skilled in the art that other parameters may be entered.
- The quantity of the therapy gas is delivered to the patient during inspiration. In one or more embodiments, the therapy gas is delivered to the patient's alveoli. In specific embodiments, substantially all of the therapy gas is delivered to the patient's alveoli. As used in this specification and the appended claims, the term “substantially all” means that at least about 80%, 85%, 90% or 95% of the therapy gas is delivered to the alveoli. In some embodiments, “substantially all” means that a sufficient percentage of therapy gas is delivered to the alveoli so that there is little or no irritation of the respiratory track.
- Delivery of the therapy gas to the patient happens every nth breath during the plurality of breaths. In detailed embodiments, n is 1 or greater. When n is 1, the therapy gas is delivered to the patient on each breath. Where n is 2, the therapy gas is delivered to the patient on every other breath. In various embodiments, n is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. Thus, when n is 2 or greater, conditions of skipped breathing are achieved, meaning therapy gas is skipped on certain breaths while administered on certain other breaths. Additionally, the interval between delivery breaths can vary throughout the delivery of the total quantity depending on a number of conditions. For example, therapy gas may be delivered on
breaths - Furthermore, certain embodiments provide that the delivery every nth breath does not need to follow a specific pattern. For example, as discussed in more detail below, certain breaths may be skipped for a variety of reasons, such as an amount to be delivered in a particular breath being less than a minimum delivery quantity. Breaths may also be skipped such that the gas is not delivered on literally every nth breath, but the therapy gas is delivered on average every nth breath. Also, the value of n may change during administration such that the therapy gas is delivered is every n1 th breath for part of the administration, the therapy gas is delivered is every n2 th breath for another part of the administration, the therapy gas is delivered every n3 th breath for a third part of the administration, etc.
- In some embodiments, the quantity of therapy gas provided at the nth breath is a function of one or more of a first respiratory rate, a first tidal volume of the patient and the patient's ideal body weight. The first respiratory rate and tidal volume can be measured prior to, at the beginning of, or during the treatment. One or more of the first respiratory rate and tidal volume can be used to calculate an initial amount of therapy gas to be delivered on each nth breath for a period of time to deliver the desired total quantity of therapy gas. After this initial respiratory rate is measured and the initial amount to be delivered per nth breath is calculated or determined, changes in the respiratory rate may occur and the calculated amount may need to be adjusted. Thus, a subsequent calculation of the amount of therapy gas to be delivered can be performed. The subsequent calculation can be done after any or all individual administration of therapy gas. In one embodiment, the amount of therapy gas to be delivered during the nth breath can be recalculated after each individual delivery. As a result of the recalculations, the total quantity of therapy gas delivered is independent of the patient's respiratory rate, and the total quantity of therapy gas can be controlled to be the desired amount.
- As an example, should the initial amount of therapy gas to be delivered during the nth breath be calculated to amount to 100 μL, and after the first breath, the patients respiratory rate doubles, the subsequent calculated rate would be about 50 μL per nth breath. In the prior art, which does not recalculate the amount of therapy gas to be delivered, this scenario would result in the patient having received about twice the amount of therapy gas as was originally intended by the end of the period of time for delivery of the gas. Thus, recalculating the amount of gas to be delivered throughout the delivery period may result in a more accurate amount of therapy gas provided to the patient and can help mitigate potential side effects of too much of the therapy gas. Accordingly, varying the amount per nth breath ensures that the desired total amount of therapy gas is delivered to the patient over the plurality of breaths.
- The quantity of the therapy gas per nth breath can be varied to ensure that the desired total quantity over the period of time is administered, independent of the respiratory pattern of the patient. The quantity of therapy gas delivered may be in the range of a minimum quantity and a maximum quantity. In detailed embodiments, the minimum quantity and maximum quantity are functions of the device delivering the therapy gas. The minimum quantity may be the smallest amount that the device is capable of providing and the maximum quantity may be the maximum amount that the device is capable of providing. For example, if the smallest volume of therapy gas that the device is capable of releasing is 10 μL, then the concentration of the therapy gas multiplied by the smallest deliverable volume will give the smallest amount of therapy gas active that can be delivered.
- In some embodiments, when the quantity of therapy gas to be delivered per nth breath is greater than the minimum quantity and less than the maximum quantity, the quantity of therapy gas per breath is administered on the nth breath. When the quantity of therapy gas per nth breath is less than the minimum, the therapy gas can be administered in many ways. For example, if the device is only capable of delivering a minimum of 10 μL, but the quantity to be delivered is 8 μL, the device can skip the amount to be delivered during this breath and add the amount (8 μL) to any of the subsequent breaths, or can divide the amount among two or more subsequent breaths. Alternatively, the device can deliver the minimum amount to be delivered (10 μL) and subtract the difference (2 μL) from a subsequent breath or divided the amount to be subtracted over two or more subsequent breaths. In detailed embodiments, the quantity of therapy gas per breath is skipped and a new quantity of therapy gas per breath is calculated for subsequent doses. The new quantity can include the skipped amount in a single breath, or the new quantity can spread the skipped amount over multiple breaths.
- When the quantity of therapy gas to be delivered for the nth breath is greater than the maximum quantity, several potential courses of action can be taken, including triggering an alarm. In detailed embodiments, the maximum quantity of therapy gas per breath is administered and the difference between the calculated quantity of therapy gas for the nth breath and the maximum quantity of therapy gas is carried forward for later delivery on one or more subsequent breaths. However, where later delivery is not possible, the system may trigger one of many alarm conditions or can be set to automatically extend the period of time for delivery to ensure that the desired total amount of therapy gas is delivered.
- In some embodiments, n is 1 such that the therapy gas is administered every breath. However, even if the therapy gas is set to be administered every breath, some breaths may be skipped if the amount to be delivered in a given breath is less than the minimum quantity. As noted above, the quantity that would have been delivered during this skipped breath may be added to any of the subsequent breaths or may be divided among two or more subsequent breaths.
- In some embodiments, the therapy gas is administered every nth breath where n is 2 or greater. This means that the therapy gas is provided in a “skip breathing” regimen. Skip breathing may be desired as there can be an overall decrease in the amount and severity of adverse reactions including irritation due to the therapy gas. In some embodiments, where n is 2 or greater, the therapy gas is delivered during every other (for n=2) breath, or greater, and no therapy gas is administered during the other breaths. During the alternate breaths (i.e., where no therapy gas is provided) the patient can breathe ambient air, oxygenated air, pure oxygen, or a different therapy gas, depending on the desired treatment. In detailed embodiments, the patient breathes ambient air on inhalations not accompanied by therapy gas.
- In some embodiments, where n is 2 or greater, the administration of quantities greater than the maximum amount can be handled differently than when therapy gas is delivered on every breath. If the amount to be delivered is greater than the maximum, the device may proceed in one or more of the following manners: (a) an alarm can be activated; (b) the maximum amount of therapy gas that can be delivered is delivered to the patient on the nth breath; and (c) the difference between the maximum amount and the quantity to be delivered is carried over to subsequent breaths or administrations. If the following breath is skipped as part of a skip breathing protocol, i.e. is not an nth breath, the carryover dose could be provided during the skipped breath or maintained until the next breath scheduled for dosing.
- The amount of therapy gas to be delivered can be calculated multiple times during the total administration time. The amount can be recalculated based on the number of breaths, the amount of time between measurements and after every breath, as desired by the administration protocol. When the quantity of the therapy gas to be delivered is skipped, for any reason, a new quantity of therapy gas per breath is calculated.
- Upon completion of the administration program, one or more of several actions can be taken by the device. The device can trigger an alarm, as described earlier. The administration can continue until manually or programmatically stopped. The delivery program (i.e., the amount of therapy gas per period of time) can be repeated for any number of repetitions, or indefinitely. The administration of the therapy gas can be stopped until manually or programmatically restarted (i.e., a programmed pause between executions of the administration protocol). For example, if the program calls for delivery over a one hour period, the device can be programmed to wait for a specified period (e.g., 2 hours) after completion before restarting the administration program.
- Additional embodiments of the invention are directed to methods of treating pulmonary arterial hypertension (PAH), including those suffering from chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), etc. A desired total quantity of therapy gas to be delivered to a COPD patient over a period of time over a plurality of breaths is determined. The quantity is administered to the patient during inspiration every nth breath of the plurality of breaths, where n is 2 or greater. The quantity of therapy gas is varied per breath to ensure that the desired total quantity delivered over the period of time is maintained independent of the respiratory pattern of the patient. In detailed embodiments, varying the quantity of the therapy gas per breath comprises determining the quantity of therapy gas to be delivered during the breath based on the respiratory rate of the patient and the amount of therapy gas already given to the patient. In other words, the desired total amount of therapy gas to be delivered to the patient over the plurality of breaths is ensured by varying the amount delivered per breath, as required by changes in the breathing pattern of the patient.
-
FIG. 5 shows a flowchart for adetailed method 100 in accordance with one or more embodiments of the invention. It will be understood by those skilled in the art that the method outlined inFIG. 5 is merely a possible methodology and should not be taken as limiting the scope of the invention. The methods described provide for ability to manage the total quantity of therapy gas given over a period of time. Pertinent information related to the administration of the therapy gas and theprogram conditions 102 are entered into a device capable of delivering the therapy gas. The program conditions can explicitly state the necessary information for delivery, or can provide variables which the device can use to calculate the necessary information. - The device determines if the approaching breath is an nth breath 104, meaning that the device will administer the therapy gas on that breath. On a first pass through the process flow, the answer will likely be yes, leading the device to determine one or more
physiological parameters 106 of the patient (e.g., respiratory rate and tidal volume). The physiological parameters can be measured by the device or transferred from another measuring device or can be manually entered into the device. - Based on the measurements of the physiological parameters, the device can calculate the amount of therapy gas to be delivered to the
patient 108. This can be an initial calculation or a subsequent calculation. The calculated amount of therapy gas per breath may be compared 110 to a minimum quantity and a maximum quantity of deliverable gas. The minimum and maximum quantities, as described previously, can be functions of the device, functions of the concentration of the therapy gas source, a function of the physiological parameters of the patient and combinations thereof. If the amount of therapy gas to be delivered is between the minimum and maximum quantities, the dose of therapy gas is delivered 112 to the patient on the next breath. - If the comparison in 110 indicated that the amount of therapy gas to be delivered is less than the minimum deliverable amount, the device can proceed with any or all of several below
minimum amount options 114. The device can withholdadministration 116 of the therapy gas for that breath. The device can carryover 118 the amount not administered to one or more subsequent breaths. The minimum amount can be administered 120 resulting in an over-administration for that breath. The amount over-administered can then be reduced from one or more subsequent breaths. An alarm condition 122 (e.g., audible, visual, or electronic), as described earlier, can be activated. - If the comparison in 110 indicates that the amount of therapy gas to be delivered is greater than the maximum deliverable amount, the device can proceed with any or all of several above
maximum amount options 124. The device can trigger analarm condition 122 as described above. The device can administer themaximum amount 126 and either discard the difference orcarryover 118 the difference to subsequent breaths. However, depending on the reason for the quantity to be delivered to be over the maximum and the administration protocol, carrying over the difference to subsequent breaths can result in the amount for each nth breath to be over the maximum. To avoid this, the device can be programmed to carryover the amount if, for example, the calculated amount to be delivered is an outlier or if subsequent breaths are skipped. - After the amount of therapy gas is delivered (if applicable), the device determines if it has reached the
end conditions 128 of the program (e.g., time, amount delivered, number of breaths). If the end condition has not been reached, the device can then check to see if the next breath is scheduled to receive a dose oftherapy gas 104. If yes, the method proceeds through one or more of the steps as previously described. If the following breath is not supposed to receive therapy gas, the device can determine if there is carryover from aprevious breath 130. If there is carryover and it is the delivery of therapy gas is allowed on the alternate breaths, the device can determine the amount of therapy gas per breath to deliver 108. This can be as simple as delivering the carried over amount, or holding the amount for further subsequent breaths. If there are no carry overbreaths 130, the device can do nothing for the breath and restart the method at evaluating if the next breath is an nth breath 104. - When the
end conditions 128 have been met, the method and device can proceed through one or more of variousend condition actions 132. The delivery of the therapy gas can be discontinued until manually or programmatically restarted 134. An alarm can be triggered. Administration of the therapy gas can continue 136 under the same conditions (e.g., restarting the program 138) or with different conditions. - Those skilled in the art will readily recognize numerous adaptations and modifications which can be made to the pharmaceutical gas delivery system and method of delivering a pharmaceutical gas of the present invention which will result in an improved method and system for introducing a known desired quantity of a pharmaceutical gas into a patient, yet all of which will fall within the scope and spirit of the present invention as defined in the following claims. Accordingly, the invention is to be limited only by the following claims and their equivalents.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/215,686 US20210213235A1 (en) | 2005-09-21 | 2021-03-29 | Systems And Methods Of Administering A Pharmaceutical Gas To A Patient |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/231,554 US7523752B2 (en) | 2005-09-21 | 2005-09-21 | System and method of administering a pharmaceutical gas to a patient |
US12/430,220 US8091549B2 (en) | 2005-09-21 | 2009-04-27 | System and method of administering a pharmaceutical gas to a patient |
US13/284,433 US8397721B2 (en) | 2005-09-21 | 2011-10-28 | System and method of administering a pharmaceutical gas to a patient |
US13/287,663 US8517015B2 (en) | 2005-09-21 | 2011-11-02 | System and method of administering a pharmaceutical gas to a patient |
US13/331,807 US8893717B2 (en) | 2005-09-21 | 2011-12-20 | Systems and methods of administering a pharmaceutical gas to a patient |
US14/551,186 US10099029B2 (en) | 2005-09-21 | 2014-11-24 | Systems and methods of administering a pharmaceutical gas to a patient |
US16/156,453 US10960169B2 (en) | 2005-09-21 | 2018-10-10 | System and method of administering a pharmaceutical gas to a patient |
US17/215,686 US20210213235A1 (en) | 2005-09-21 | 2021-03-29 | Systems And Methods Of Administering A Pharmaceutical Gas To A Patient |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/156,453 Continuation US10960169B2 (en) | 2005-09-21 | 2018-10-10 | System and method of administering a pharmaceutical gas to a patient |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210213235A1 true US20210213235A1 (en) | 2021-07-15 |
Family
ID=46489804
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/331,807 Active 2026-11-20 US8893717B2 (en) | 2005-09-21 | 2011-12-20 | Systems and methods of administering a pharmaceutical gas to a patient |
US14/551,186 Active 2027-04-29 US10099029B2 (en) | 2005-09-21 | 2014-11-24 | Systems and methods of administering a pharmaceutical gas to a patient |
US16/156,453 Active US10960169B2 (en) | 2005-09-21 | 2018-10-10 | System and method of administering a pharmaceutical gas to a patient |
US17/215,686 Abandoned US20210213235A1 (en) | 2005-09-21 | 2021-03-29 | Systems And Methods Of Administering A Pharmaceutical Gas To A Patient |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/331,807 Active 2026-11-20 US8893717B2 (en) | 2005-09-21 | 2011-12-20 | Systems and methods of administering a pharmaceutical gas to a patient |
US14/551,186 Active 2027-04-29 US10099029B2 (en) | 2005-09-21 | 2014-11-24 | Systems and methods of administering a pharmaceutical gas to a patient |
US16/156,453 Active US10960169B2 (en) | 2005-09-21 | 2018-10-10 | System and method of administering a pharmaceutical gas to a patient |
Country Status (1)
Country | Link |
---|---|
US (4) | US8893717B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220034764A1 (en) * | 2018-12-03 | 2022-02-03 | Mallinckrodt Hospital Products IP Unlimited Company | Gas sensor module |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9026370B2 (en) | 2007-12-18 | 2015-05-05 | Hospira, Inc. | User interface improvements for medical devices |
AU2012299169B2 (en) | 2011-08-19 | 2017-08-24 | Icu Medical, Inc. | Systems and methods for a graphical interface including a graphical representation of medical data |
US10022498B2 (en) | 2011-12-16 | 2018-07-17 | Icu Medical, Inc. | System for monitoring and delivering medication to a patient and method of using the same to minimize the risks associated with automated therapy |
EP2827932B1 (en) | 2012-03-19 | 2020-06-03 | Thornhill Scientific Inc. | Virtual respiratory gas delivery systems and circuits |
JP6306566B2 (en) | 2012-03-30 | 2018-04-04 | アイシーユー・メディカル・インコーポレーテッド | Air detection system and method for detecting air in an infusion system pump |
WO2014022513A1 (en) * | 2012-07-31 | 2014-02-06 | Hospira, Inc. | Patient care system for critical medications |
US9604026B2 (en) * | 2013-02-20 | 2017-03-28 | Wisconsin Alumni Research Foundation | Medical carbon monoxide delivery system |
EP2968828B1 (en) * | 2013-03-15 | 2018-11-21 | INO Therapeutics LLC | Therapeutic gas delivery device with pulsed and continuous flow control |
AU2014268355B2 (en) | 2013-05-24 | 2018-06-14 | Icu Medical, Inc. | Multi-sensor infusion system for detecting air or an occlusion in the infusion system |
WO2014194065A1 (en) | 2013-05-29 | 2014-12-04 | Hospira, Inc. | Infusion system and method of use which prevents over-saturation of an analog-to-digital converter |
CA2913915C (en) | 2013-05-29 | 2022-03-29 | Hospira, Inc. | Infusion system which utilizes one or more sensors and additional information to make an air determination regarding the infusion system |
FR3015000B1 (en) * | 2013-12-12 | 2016-05-27 | Air Liquide Sante (International) | SYSTEM FOR STORING AND DISPENSING NO / NITROGEN MIXTURES |
ES2776363T3 (en) | 2014-02-28 | 2020-07-30 | Icu Medical Inc | Infusion set and method using dual wavelength in-line optical air detection |
TW201618795A (en) * | 2014-04-15 | 2016-06-01 | 波泰里斯股份有限公司 | Systems and methods to improve organ function and organ transplant longevity |
US11344673B2 (en) | 2014-05-29 | 2022-05-31 | Icu Medical, Inc. | Infusion system and pump with configurable closed loop delivery rate catch-up |
US9950129B2 (en) | 2014-10-27 | 2018-04-24 | Covidien Lp | Ventilation triggering using change-point detection |
US11344668B2 (en) | 2014-12-19 | 2022-05-31 | Icu Medical, Inc. | Infusion system with concurrent TPN/insulin infusion |
US10850024B2 (en) | 2015-03-02 | 2020-12-01 | Icu Medical, Inc. | Infusion system, device, and method having advanced infusion features |
CN111603643B (en) | 2015-04-02 | 2023-05-23 | 希尔-罗姆服务私人有限公司 | Pressure control of breathing apparatus |
CN105288809A (en) * | 2015-11-27 | 2016-02-03 | 刘洋 | Pneumatic respirator with safety monitor function based on Internet of Things |
EP4085944A1 (en) | 2016-05-13 | 2022-11-09 | ICU Medical, Inc. | Infusion pump system with common line auto flush |
CA3027176A1 (en) | 2016-06-10 | 2017-12-14 | Icu Medical, Inc. | Acoustic flow sensor for continuous medication flow measurements and feedback control of infusion |
WO2018026671A1 (en) * | 2016-08-01 | 2018-02-08 | Gipson Keith | System and method for hypobaric oxygenation with membrane oxygenator |
RU2717525C1 (en) | 2017-02-27 | 2020-03-23 | Сёрд Поул, Инк. | Systems and methods of producing nitrogen oxide |
CN110770163B (en) | 2017-02-27 | 2021-08-31 | 第三极股份有限公司 | System and method for mobile generation of nitric oxide |
MX2020010523A (en) | 2017-02-27 | 2021-02-09 | Third Pole Inc | Systems and methods for generating nitric oxide. |
US10089055B1 (en) | 2017-12-27 | 2018-10-02 | Icu Medical, Inc. | Synchronized display of screen content on networked devices |
SG11202005975XA (en) * | 2017-12-28 | 2020-07-29 | Bellerophon Pulse Tech Llc | Pulsed administration of inhaled nitric oxide for the treatment of pulmonary hypertension |
EP3793656A1 (en) | 2018-05-14 | 2021-03-24 | Covidien LP | Systems and methods for respiratory effort detection utilizing signal distortion |
US11752287B2 (en) | 2018-10-03 | 2023-09-12 | Covidien Lp | Systems and methods for automatic cycling or cycling detection |
GB2581999B (en) | 2019-03-07 | 2023-01-04 | Bpr Medical Ltd | Gas flow alarm |
CN114375284A (en) | 2019-05-15 | 2022-04-19 | 第三极股份有限公司 | System and method for generating nitric oxide |
CN114269685A (en) | 2019-05-15 | 2022-04-01 | 第三极股份有限公司 | Electrode for nitric oxide generation |
US11278671B2 (en) | 2019-12-04 | 2022-03-22 | Icu Medical, Inc. | Infusion pump with safety sequence keypad |
EP4069069A4 (en) | 2020-01-11 | 2024-07-03 | Third Pole Inc | Systems and methods for nitric oxide generation with humidity control |
WO2021258025A1 (en) | 2020-06-18 | 2021-12-23 | Third Pole, Inc. | Systems and methods for preventing and treating infections with nitric oxide |
CA3189781A1 (en) | 2020-07-21 | 2022-01-27 | Icu Medical, Inc. | Fluid transfer devices and methods of use |
US11369763B2 (en) * | 2020-07-31 | 2022-06-28 | Soco International Llc | Respiratory ventilatory device and method of operating same |
US11135360B1 (en) | 2020-12-07 | 2021-10-05 | Icu Medical, Inc. | Concurrent infusion with common line auto flush |
CN113398398B (en) * | 2021-06-03 | 2022-02-01 | 桐乡市第一人民医院 | Dosage metering and feeding device of anesthesia machine for anesthesia department and control method |
WO2023049873A1 (en) | 2021-09-23 | 2023-03-30 | Third Pole, Inc. | Systems and methods for delivering nitric oxide |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6786217B2 (en) * | 1999-11-24 | 2004-09-07 | Sensormedics Corporation | Method and apparatus of delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6294175A (en) | 1985-10-18 | 1987-04-30 | 鳥取大学長 | Respiration synchronous type gas blowing apparatus and method |
EP0560928B1 (en) | 1990-12-05 | 1997-09-24 | The General Hospital Corporation | Use of no for the treatment or prevention of bronchoconstriction |
GB2279014B (en) | 1993-06-02 | 1997-07-16 | Niall Keaney | Device for controlling delivery of respiratory drugs |
GB9320978D0 (en) | 1993-10-12 | 1993-12-01 | Higenbottam Timohy W | Nitric oxide treatment |
US5558083A (en) | 1993-11-22 | 1996-09-24 | Ohmeda Inc. | Nitric oxide delivery system |
JP2786808B2 (en) | 1994-02-10 | 1998-08-13 | 忠道 目黒 | Measurement method of gas-phase respiratory function and health management method of gas-phase respiratory function using the measurement result |
WO1997037644A1 (en) | 1996-04-05 | 1997-10-16 | The General Hospital Corporation | Treatment of a hemoglobinopathy |
JPH10179742A (en) | 1996-12-25 | 1998-07-07 | Sumitomo Seika Chem Co Ltd | Portable nitrogen monoxide-gaseous oxygen supply device and its operation |
WO1998031282A1 (en) | 1997-01-17 | 1998-07-23 | Messer Griesheim Austria Ges.Mbh | Controlled gas-supply system |
US5918596A (en) | 1997-04-22 | 1999-07-06 | Instrumentarium Corp. | Special gas dose delivery apparatus for respiration equipment |
US6164276A (en) | 1997-05-16 | 2000-12-26 | Datex-Ohmeda, Inc. | Accurate dose nitric oxide pulse delivery device with monitoring and alarms |
US6125846A (en) | 1997-05-16 | 2000-10-03 | Datex-Ohmeda, Inc. | Purge system for nitric oxide administration apparatus |
US6371114B1 (en) | 1998-07-24 | 2002-04-16 | Minnesota Innovative Technologies & Instruments Corporation | Control device for supplying supplemental respiratory oxygen |
US6109260A (en) | 1998-02-18 | 2000-08-29 | Datex-Ohmeda, Inc. | Nitric oxide administration device with timed pulse |
US6089229A (en) | 1998-05-26 | 2000-07-18 | Datex-Ohmeda, Inc. | High concentration no pulse delivery device |
JP2000024110A (en) | 1998-07-16 | 2000-01-25 | Teijin Ltd | Respiration synchronizing-type gas supply device |
FI110065B (en) | 1998-12-08 | 2002-11-29 | Instrumentarium Oyj | Device in a feedback control system |
US7678390B2 (en) | 1999-04-01 | 2010-03-16 | Yale University | Carbon monoxide as a biomarker and therapeutic agent |
CN2368059Y (en) | 1999-04-21 | 2000-03-08 | 莫绪明 | Nitroger monoxide gas suction-flow controller |
EP1128863B1 (en) | 1999-09-22 | 2006-04-19 | Instrumentarium Corporation | Improving oxygenation in subjects suffering impaired oxygenation |
SE9903467D0 (en) | 1999-09-24 | 1999-09-24 | Siemens Elema Ab | Feedback control of mechanical breathing aid gas flow |
US7516742B2 (en) | 1999-11-24 | 2009-04-14 | Cardinal Health 207, Inc. | Method and apparatus for delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients with intermittent dosing |
CN2439288Y (en) | 2000-07-27 | 2001-07-18 | 中国人民解放军第二军医大学南京军医学院 | Nitrogen mono oxide high frequency jetting insufflator as therapeutical instrument |
US6668828B1 (en) | 2000-10-16 | 2003-12-30 | Pulmonox Technologies Corporations | System and elements for managing therapeutic gas administration to a spontaneously breathing non-ventilated patient |
JP2002143305A (en) | 2000-11-14 | 2002-05-21 | Gunma Koike:Kk | Respiration synchronization-type oxygen supplying device |
EP1395241B9 (en) | 2001-05-25 | 2005-06-15 | Medtronic, Inc. | Implantable medical device with controllable gaseous agent release system |
CA2351217C (en) | 2001-06-19 | 2008-12-02 | Teijin Limited | An apparatus for supplying a therapeutic oxygen gas |
EP1480658B1 (en) | 2002-02-13 | 2017-01-25 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating vascular disease |
CA2481972A1 (en) | 2002-04-15 | 2003-10-30 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Methods of treating ileus |
US6909912B2 (en) | 2002-06-20 | 2005-06-21 | University Of Florida | Non-invasive perfusion monitor and system, specially configured oximeter probes, methods of using same, and covers for probes |
DE10230165A1 (en) | 2002-07-04 | 2004-01-15 | Ino Therapeutics Gmbh | Method and device for the administration of carbon monoxide |
EA200500782A1 (en) | 2002-11-07 | 2005-10-27 | Юниверсити Оф Питтсбург Оф Дзе Коммонвелт Систем Оф Хайер Эдьюкейшн | TREATMENT OF HEMORRHAGIC SHOCK |
DE10306766A1 (en) | 2003-02-18 | 2004-08-26 | Ino Therapeutics Gmbh | Dosed delivery of a therapeutic gas |
DE10321448A1 (en) | 2003-05-13 | 2004-12-02 | Ino Therapeutics Gmbh | Method and device for the controlled admixing of a gas or gas mixture to a gas (mixture) stream |
CN1950120B (en) | 2004-05-11 | 2010-10-20 | 伟亚医疗森迪斯公司 | Intermittent dosing of nitric oxide gas |
US7690378B1 (en) | 2004-07-21 | 2010-04-06 | Pacesetter, Inc. | Methods, systems and devices for monitoring respiratory disorders |
US7370651B2 (en) | 2005-04-01 | 2008-05-13 | Ric Investments, Llc | Gas conserving device |
US7523752B2 (en) | 2005-09-21 | 2009-04-28 | Ino Therapeutics, Llc | System and method of administering a pharmaceutical gas to a patient |
US7305988B2 (en) | 2005-12-22 | 2007-12-11 | The General Electric Company | Integrated ventilator nasal trigger and gas monitoring system |
US10960168B2 (en) | 2008-08-21 | 2021-03-30 | Vero Biotech LLC | Delivery of high concentration nitric oxide |
US20100175695A1 (en) | 2009-01-12 | 2010-07-15 | Mindray Ds Usa, Inc. | Auxiliary gas mixing in an anesthesia system |
-
2011
- 2011-12-20 US US13/331,807 patent/US8893717B2/en active Active
-
2014
- 2014-11-24 US US14/551,186 patent/US10099029B2/en active Active
-
2018
- 2018-10-10 US US16/156,453 patent/US10960169B2/en active Active
-
2021
- 2021-03-29 US US17/215,686 patent/US20210213235A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6786217B2 (en) * | 1999-11-24 | 2004-09-07 | Sensormedics Corporation | Method and apparatus of delivery of inhaled nitric oxide to spontaneous-breathing and mechanically-ventilated patients |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220034764A1 (en) * | 2018-12-03 | 2022-02-03 | Mallinckrodt Hospital Products IP Unlimited Company | Gas sensor module |
Also Published As
Publication number | Publication date |
---|---|
US20150075526A1 (en) | 2015-03-19 |
US8893717B2 (en) | 2014-11-25 |
US10960169B2 (en) | 2021-03-30 |
US20190038864A1 (en) | 2019-02-07 |
US10099029B2 (en) | 2018-10-16 |
US20120180790A1 (en) | 2012-07-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210213235A1 (en) | Systems And Methods Of Administering A Pharmaceutical Gas To A Patient | |
US20200163989A1 (en) | System And Method Of Administering A Pharmaceutical Gas To A Patient | |
AU2022200379B2 (en) | System and method of administering a pharmaceutical gas to a patient | |
AU2020202875A1 (en) | System and method of administering a pharmaceutical gas to a patient | |
AU2015201474B2 (en) | System and method of administering a pharmaceutical gas to a patient | |
MX2008003829A (en) | System and method of administering a pharmaceutical gas to a patient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT, DELAWARE Free format text: SECURITY INTEREST;ASSIGNORS:MALLINCKRODT ENTERPRISES LLC;MALLINCKRODT LLC;SPECGX LLC;AND OTHERS;REEL/FRAME:060389/0913 Effective date: 20220616 |
|
AS | Assignment |
Owner name: DEUTSCHE BANK AG NEW YORK BRANCH, NEW YORK Free format text: NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY;ASSIGNORS:MALLINCKRODT ENTERPRISES LLC;MALLINCKRODT LLC;SPECGX LLC;AND OTHERS;REEL/FRAME:060434/0536 Effective date: 20220616 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
AS | Assignment |
Owner name: ACQUIOM AGENCY SERVICES LLC, COLORADO Free format text: SECURITY INTEREST;ASSIGNORS:MALLINCKRODT ENTERPRISES LLC;MALLINCKRODT LLC;MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY;AND OTHERS;REEL/FRAME:065595/0376 Effective date: 20231114 Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: VTESSE LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY, IRELAND Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 Owner name: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.), MISSOURI Free format text: RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913;ASSIGNOR:WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT;REEL/FRAME:065583/0465 Effective date: 20231114 |
|
AS | Assignment |
Owner name: SUCAMPO PHARMA AMERICAS LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED, IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY, IRELAND Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: VTESSE LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: STRATATECH CORPORATION, WISCONSIN Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: OCERA THERAPEUTICS, INC., MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: SPECGX LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: MALLINCKRODT LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 Owner name: MALLINCKRODT ENTERPRISES LLC, MISSOURI Free format text: RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536;ASSIGNOR:DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT;REEL/FRAME:065601/0347 Effective date: 20231114 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |